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Background: Approximately 10–15% of the adult population suffer from gallstone disease, cholelithiasis,
with more women than men being affected. Cholecystectomy is the treatment of choice for people who
present with biliary pain or acute cholecystitis and evidence of gallstones. However, some people do not
experience a recurrence after an initial episode of biliary pain or cholecystitis. As most of the current
research focuses on the surgical management of the disease, less attention has been dedicated to the
consequences of conservative management.
Objectives: To determine the clinical effectiveness and cost-effectiveness of cholecystectomy compared
with observation/conservative management in people presenting with uncomplicated symptomatic
gallstones (biliary pain) or cholecystitis.
Data sources: We searched all major electronic databases (e.g. MEDLINE, EMBASE, Science Citation Index,
Bioscience Information Service, Cochrane Central Register of Controlled Trials) from 1980 to September
2012 and we contacted experts in the ﬁeld.
Review methods: Evidence was considered from randomised controlled trials (RCTs) and non-randomised
comparative studies that enrolled people with symptomatic gallstone disease (pain attacks only and/or
acute cholecystitis). Two reviewers independently extracted data and assessed the risk of bias of included
studies. Standard meta-analysis techniques were used to combine results from included studies. A de novo
Markov model was developed to assess the cost-effectiveness of the interventions.
Results: Two Norwegian RCTs involving 201 participants were included. Eighty-eight per cent of people
randomised to surgery and 45% of people randomised to observation underwent cholecystectomy during
the 14-year follow-up period. Participants randomised to observation were signiﬁcantly more likely to
experience gallstone-related complications [risk ratio = 6.69; 95% conﬁdence interval (CI) 1.57 to 28.51;
p = 0.01], in particular acute cholecystitis (risk ratio = 9.55; 95% CI 1.25 to 73.27; p = 0.03), and less likely
to undergo surgery (risk ratio = 0.50; 95% CI 0.34 to 0.73; p = 0.0004), experience surgery-related
complications (risk ratio = 0.36; 95% CI 0.16 to 0.81; p = 0.01) or, more speciﬁcally, minor surgery-relatedv
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ABSTRACT
vicomplications (risk ratio = 0.11; 95% CI 0.02 to 0.56; p = 0.008) than those randomised to surgery.
Fifty-ﬁve per cent of people randomised to observation did not require an operation during the 14-year
follow-up period and 12% of people randomised to cholecystectomy did not undergo the scheduled
operation. The results of the economic evaluation suggest that, on average, the surgery strategy costs
£1236 more per patient than the conservative management strategy but was, on average, more effective.
An increase in the number of people requiring surgery while treated conservatively corresponded to a
reduction in the cost-effectiveness of the conservative strategy. There was uncertainty around some of the
parameters used in the economic model.
Conclusions: The results of this assessment indicate that cholecystectomy is still the treatment of choice
for many symptomatic people. However, approximately half of the people in the observation group did not
require surgery or suffer complications in the long term indicating that a conservative therapeutic approach
may represent a valid alternative to surgery in this group of people. Owing to the dearth of current
evidence in the UK setting a large, well-designed, multicentre trial is needed.
Study registration: The study was registered as PROSPERO CRD42012002817
Funding: The National Institute for Health Research Health Technology Assessment programme.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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Gallstones are common, especially in women, but in many people they do not cause any symptoms.
About one in three people with gallstones develop symptoms. Symptoms usually include a severe pain in
the upper right-hand side of the abdomen (known as ‘biliary colic’), and sometimes nausea and vomiting.
Sometimes the pain is accompanied by inﬂammation of the gallbladder (cholecystitis).
Once gallstones start giving symptoms, painkillers, anti-inﬂammatory medicines and antibiotics are
usually prescribed.
Surgery to remove the gallbladder, known as cholecystectomy, is the most common way to treat biliary
pain or cholecystitis due to gallstones. About 70,000 cholecystectomies are performed every year in the
UK, with signiﬁcant costs for the NHS.
In the UK, surgery is commonly offered to people who present at secondary care with pain or cholecystitis
due to gallstones. However, it is known that some patients do not have any more symptoms after the
initial episode of pain and that surgery may not be necessary. This assessment has shown that some
people with mild symptoms do not experience a recurrence or suffer complications for many years.
A policy of ‘conservative treatment’ (painkillers/antibiotics and lifestyle advice) could, therefore, be
appropriate in this group of people. Our results indicate that, for the NHS, surgery is more expensive
than ‘conservative treatment’ but is still the most clinically effective treatment for gallstones.
There are, however, great uncertainties in the data. There is a need for new clinical studies to
address these uncertainties.xv
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Gallstone disease, cholelithiasis, is the most common and costly gastrointestinal disorder in industrialised
countries. Prevalence increases with age and obesity and is higher in women than in men.
In about 20% of people, the condition is symptomatic and can cause severe pain and complications which
require medical attention and/or emergency surgery. Cholecystectomy, the surgical removal of the
gallbladder, is the treatment of choice for people who present with biliary pain or acute cholecystitis and
evidence of gallstones. Nowadays cholecystectomy is performed preferably by means of laparoscopic
procedures. However, some people, after an initial episode of biliary pain or cholecystitis, do not
experience persistent symptoms or complications. Natural history and population-based studies have
shown that around half of symptomatic people do not experience further episodes of pain. There is,
therefore, an indication that uncomplicated symptomatic gallstone disease (biliary pain or cholecystitis)
does not always require removal of the gallbladder and could be treated conservatively. This assessment
was designed to help inform decisions regarding the use in clinical practice of conservative management
and cholecystectomy for adults with uncomplicated symptoms or cholecystitis. In particular, this assessment
aimed to:
l describe the clinical care pathways of uncomplicated symptomatic gallstone disease (biliary pain or
cholecystitis) in a UK NHS context
l determine the clinical effectiveness and safety of conservative management compared with
cholecystectomy
l perform a systematic review of the evidence available on the cost-effectiveness of cholecystectomy
compared with conservative management
l determine which treatment option is most likely to be cost-effective for implementation in the UK NHS
l identify and prioritise future research needs.Methods
We searched major bibliographic electronic databases from 1980 to September 2012 including MEDLINE,
MEDLINE In-Process & Other Non-Indexed Citations, EMBASE, the Science Citation Index, Bioscience
Information Service and the Cochrane Central Register of Controlled Trials. Reports of relevant evidence
syntheses were also sought from the Cochrane Database of Systematic Reviews and the Database of
Abstracts of Review of Effects. Evidence was considered from randomised controlled trials (RCTs) or
non-randomised comparative studies in which people received either cholecystectomy or observation/
conservative management. The population was adults with ﬁrst episode of symptomatic gallstone disease
(biliary pain or cholecystitis) being considered for surgical treatment in a secondary care setting. The
intervention considered was cholecystectomy (open or laparoscopic). The comparator was observation
and/or conservative management. One reviewer screened the titles and abstracts of all reports identiﬁed
by the search strategies and two reviewers independently screened all full-text papers retrieved for this
assessment. Two reviewers independently extracted data and assessed the risk of bias of included studies.
Standard meta-analysis techniques were used to combine results from included studies.
A de novo Markov model was developed to assess the cost-effectiveness of observation/conservative
management compared with cholecystectomy. Parameter estimates were derived from the systematic
review of clinical effectiveness, current literature, the expert advisory group for this assessment and other
UK sources. The outputs of the model were costs and quality-adjusted life-years (QALYs) for eachxvii
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xviiitreatment strategy, incremental costs and QALYs and incremental cost per QALY for a 5-year time horizon.
Costs were considered from a health services perspective. Costs were discounted at 3.5% per year in
accordance with the current National Institute for Health and Care Excellence guidelines. Probabilistic and
deterministic sensitivity analyses were applied to the model in order to assess the robustness of the results
to realistic variations in the model parameters.ResultsClinical effectiveness
The literature searches identiﬁed 6779 potentially relevant citations, of which 73 reports were selected
for full-text eligibility screening. Two RCTs published in six reports and involving 201 participants were
subsequently deemed suitable for inclusion. Both trials, conducted in Norway, were considered to be at
low risk of bias for all assessed quality domains. The results demonstrated that 88% of people randomised
to surgery and 45% of people randomised to observation eventually underwent cholecystectomy during
the 14-year follow-up period. Participants randomised to observation were signiﬁcantly more likely to
experience gallstone-related complications [risk ratio = 6.69; 95% conﬁdence interval (CI) 1.57 to 28.51;
p = 0.01], in particular acute cholecystitis (risk ratio = 9.55; 95% CI 1.25 to 73.27; p = 0.03), and less likely
to undergo surgery (risk ratio = 0.50; 95% CI 0.34 to 0.73; p = 0.0004), experience surgery-related
complications (risk ratio = 0.36; 95% CI 0.16 to 0.81; p = 0.01) or, more speciﬁcally, minor surgery-related
complications (risk ratio = 0.11; 95% CI 0.02 to 0.56; p = 0.008) than those participants randomised
to surgery. Among participants with an initial diagnosis of uncomplicated symptomatic gallstones (biliary
pain only) rather than cholecystitis, those randomised to observation were signiﬁcantly more likely to
experience pain attacks after randomisation (χ2 = 9.10; p = 0.0026) and to be admitted to hospital for
gallstone-related pain (χ2 = 7.79; p = 0.0053) than those randomised to surgery. Mortality risk was greater
(but not signiﬁcantly greater) among participants randomised to surgery. Fifty-ﬁve per cent of people
randomised to observation did not require an operation during the 14-year follow-up period and 12% of
people randomised to cholecystectomy did not undergo the scheduled operation.Cost-effectiveness
The results of the economic evaluation showed that, on average, the surgery strategy cost £1236 more
than the conservative management strategy but was, on average, more effective, and generated
0.094 additional QALYs. The incremental cost per QALY was £13,205. The result of the incremental
cost-effectiveness analysis indicated that the conservative management strategy had a 51% chance of
being considered cost-effective when society’s willingness to pay for a QALY was £20,000 and a 46%
chance when wilingness to pay was £30,000. The probability of cost-effectiveness was not sensitive
to changes in the threshold, when the threshold increased to £30,000, the surgery strategy had a 51%
chance of being considered cost-effective. The results were sensitive to the probability of people in
conservative management undergoing cholecystectomy. An increase in the number of people requiring
surgery while treated conservatively corresponded to a reduction in the cost-effectiveness of the
conservative strategy. There was uncertainty around the estimate derived from the meta-analysis of clinical
effectiveness. On average, the cost of the conservative management strategy was reduced to £694 when
the probability of undergoing surgery was reduced to 25%, leading to an incremental cost-effectiveness
ratio (ICER) of £33,542 per QALY for the surgical strategy. In contrast, the cost of the conservative
management strategy increased to £1757, leading to a reduced ICER of £4291 when the probability of
surgery among people initially managed conservatively was increased to 75%.Strengths and limitations
The methods used to conduct this assessment were detailed and thorough. The main limitation of this
assessment was the limited data currently available on the clinical effectiveness and safety of observation/
conservative management compared with cholecystectomy for the treatment of uncomplicated
symptomatic gallstone disease (biliary pain or cholecystitis) in the UK. The paucity of both utility and clinical
effectiveness data added uncertainty to the economic evaluation.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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The results of this assessment showed that approximately half of the people in the observation group were
eventually operated on. Participants who underwent cholecystectomy experienced more surgery-related
complications and showed a slight, non-signiﬁcant, increase in the rate of all-cause mortality than those
who were treated conservatively. In contrast, participants allocated to observation had more episodes
of cholecystitis, but few other gallstone-related complications (e.g. common bile duct stones, acute
pancreatitis). Approximately half of the people in the observation group did not require surgery in the long
term, indicating that there is probably a subgroup of people with uncomplicated symptomatic gallstones
who could beneﬁt from conservative management.
Cholecystectomy is more costly to the NHS because of the use of resources associated with surgery and
the costs related to the treatment of post-surgery complications. Our modelling shows that conservative
management is, on average, less costly but also less clinically effective for the treatment of symptomatic
gallstones. A policy of surgery for all, rather than a policy of conservative management followed by surgery
among people whose symptoms persist, is likely to be more effective even though more costly. The
difference between the two policies, however, is small. Uncertainty in the economic model was mostly
driven by the pre- and post-surgery utility values, as well as by the future probability of receiving surgery
following a strategy of conservative management.Recommendations for future research
l A large, well-designed clinical trial needs to be undertaken to compare the effects and safety of
observation/conservative management with cholecystectomy in people presenting with uncomplicated
symptomatic gallstones (biliary pain) or cholecystitis to secondary care. This trial would contribute to
identify factors which may allow the clinicians to single out people who are more likely to beneﬁt from
surgery from those at low risk of subsequent events and complications. Ideally, such a trial would
include relevant outcome measures, such as post-cholecystectomy symptoms and quality-of-life
measurements, and a full economic evaluation.
l Further research to evaluate the natural history of symptomatic gallstone disease (including
uncomplicated cases).
l Research to elicit factors that may predict the evolution of symptoms in people with symptomatic
gallstone disease.
l Research on people’s personal preferences in terms of treatment options and outcomes.
l Research to identify resource use for people undergoing cholecystectomy (pre-operative assessment,
surgical admissions and post-operative management) and for those receiving conservative
management, in order to develop more robust cost estimates for the UK.Study registration
This study is registered as PROSPERO CRD42012002817Funding
The National Institute for Health Research Health Technology Assessment programme.xix
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Introduction
Gallstone disease (cholelithiasis) is one of the most common and costly gastrointestinal disorders in
industrialised societies.1–4 The prevalence of gallstones in these adult populations is approximately
10–15%.1,5–9 Gallstones are more common in women and people over the age of 40 years.10
Approximately 80% of people with cholelithiasis do not have symptoms,11,12 can remain asymptomatic
for many years and do not require treatment.13,14 About 20% of people experience pain and clinical
complications.1,5,6,15
Surgery remains the treatment of choice for symptomatic gallstones,16 even though early natural history
studies showed that recurrent pain attacks may diminish in up to half of symptomatic people.17 As
many studies have concentrated on the best timing of performing surgery and on operative outcomes
and complications, the question whether or not cholecystectomy is always required in people with mild,
uncomplicated symptomatic gallstones has not been rigorously evaluated. There is evidence to show
that it is feasible to conduct randomised controlled trials (RCTs) to compare the effects and safety of
cholecystectomy with those of observation/conservative treatment.18
The aim of the present assessment is to evaluate the clinical effectiveness and cost-effectiveness of
cholecystectomy compared with observation/conservative management for preventing recurrent symptoms
and complications in adults presenting initially with uncomplicated symptomatic gallstones for whom
surgery is considered a treatment option.Aetiology, pathophysiology and clinical presentation
The gallbladder is a pear-shaped pouch which stores and concentrates bile entering the organ via the
hepatic and cystic ducts (Figure 1). The concentrated bile is later ejected into the duodenum in response to
food entering the intestines. The gallbladder is located beneath the liver and can hold between 30 and
50ml of bile. Histologically, the gallbladder wall consists of serous, muscular and mucous layers.19
Gallstones are solid accumulations of either cholesterol, mucin, calcium bilirubinate or protein20 and occur
when the constituents come out of solution.21 Most gallstones (> 80%) consist largely of cholesterol,7,22
whereas pigment stones consist of calcium bilirubinate and mucin glycoproteins. Both types of gallstone
form in the gallbladder itself.
Known risk factors for adults with gallstone disease include:8,23
l increasing age
l obesity
l family history of gallstone disease
l ethnicity
l recent weight loss (for example, crash diets or weight-loss surgery)
l digestive disorders (e.g. Crohn’s disease, irritable bowel syndrome)
l cirrhosis
l diabetes.1
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FIGURE 1 Biliary system. Source: http://www.daviddarling.info/encyclopaedia/G/gall_bladder.html (last accessed
May 2013). Reproduced with permission of David Darling.
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2Women who:
l take oral contraception
l have high-dose oestrogen therapy or
l are pregnant
are at higher risk (twice as likely as men) of developing gallstones. Some risk factors are modiﬁable, such
as diet and obesity, while others are not (e.g. sex, age, concomitant diseases).22
The most relevant symptom of gallstone disease is pain (i.e. biliary colic). Typically, biliary colic is deﬁned as
pain, moderate to severe, localised to the right upper quadrant or epigastrium lasting more than half an
hour which occasionally can radiate to the right scapula. The pain may be accompanied by nausea and
vomiting, may occur post-prandially and may wake the person at night. Although biliary pain is speciﬁc to
gallstone disease, many people may present with other abdominal symptoms.24 In some people, the
symptoms are mild and consist of vague indigestion or dyspepsia. Dyspeptic symptoms (e.g. belching,
bloating, heartburn), however, are not speciﬁc to gallstone disease.5,7,25Epidemiology and prognosis
Diseases of the gallbladder are widespread, affecting approximately 10–15% of the adult population.26
Clinical surveys conducted in Europe, North and South America and Asia indicate that the prevalence rates
for gallstone disease range from 5.9% to 25%27–37 and tend to increase with age. A clinical ultrasound
survey conducted in the UK reported prevalence rates of 12% among men and 22% among women over
60 years of age.35 A multicentre, population-based study conducted in Italy has reported a cumulative
incidence of gallstone disease of 0.67% per year (0.66% in men and 0.81% in women).38 In the
developed world, gallstone disease is the most common gastrointestinal complaint for which people are
admitted to hospital.2,10,39 Hospital admissions increased in England by 30% in men and by 64% in
women from 1989–90 to 1999–2000.3
Natural history studies have shown low mortality from gallstone disease, with typically < 1% of people
dying from gallbladder-related causes.3,12,13,17 The natural course of gallstone disease is benign, with a
relatively low progression from asymptomatic disease to symptomatic disease. In a recent population-based
study, the overall frequency of symptom development in asymptomatic people was around 20% over a
long follow-up period (mean 8.7 years).12 An early natural history study (in which people were found to
have gallstones through routine screening), showed that 10%, 15% and 18% of people assessed became
symptomatic at 5, 10 and 15 years, respectively.40NIHR Journals Library www.journalslibrary.nihr.ac.uk
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0.1–0.2%. In contrast, in people with symptomatic gallstone disease, the annual rates of developing
complications have been reported to be higher, 1–3%.41–43 The Italian Group for the Epidemiology and
Prevention of Cholelithiasis study reported an annual incidence of complications of 0.3% for asymptomatic
people and 0.7% for symptomatic people.13 In particular, there is a proportion of people with
uncomplicated gallstone disease who may experience only a few episodes of biliary pain without
developing serious symptoms or complications for many years.44,45 A recent multicentre study found that a
considerable proportion of people with mild and severe symptoms (58% and 52%, respectively) did not
experience subsequent episodes of biliary pain during the 10-year follow-up period and 10% suffered
from gallstone complications, indicating a benign course of the disease even in those with initially severe
symptoms.12 Moreover, the severity of the disease does not seem to increase over time.21,46
In the UK and in North America, the number of surgical procedures for gallstone disease increased steadily
between the 1950s and 1990s, reﬂecting both the rise in prevalence of gallstone disease and the use of
cholecystectomy as the treatment of choice.3,47 Rates of surgical procedures stabilised in both countries
towards the end of the twentieth century.3,48Impact of health problem
From a patient perspective, the deﬁning symptom of gallstone disease is pain.49,50 Commonly, general
abdominal symptoms intensify over a period of time and become regular pain attacks, which require
medical attention. Although the pain experienced may be described as ‘non-speciﬁc’,7,49,50 it tends to occur
in a deﬁned location and with characteristic patterns as described above. Best medical therapy includes the
prescription of analgesics and, when necessary, antibiotics.
The most common complications associated with gallstones are acute cholecystitis, common bile duct
(CBD) stones and acute pancreatitis. Acute cholecystitis is caused by a gallstone obstructing the cystic duct
and results in unresolving upper right quadrant pain, nausea, vomiting, anorexia and fever.51 CBD stones
are found in up to 15% of people who undergo cholecystectomy. They may be asymptomatic or
accompanied by biliary pain, jaundice, pancreatitis or cholangitis.52 CBD stones can cause acute
pancreatitis by obstructing the main pancreatic duct.53 The typical symptoms of gallstone-related
pancreatitis are epigastric abdominal pain, nausea and vomiting.51 Pancreatitis is severe in over 20% of
people with gallstone disease and can cause death in about one-third.54
Even though removal of the gallbladder is considered the standard treatment for symptomatic gallstones,
it does not guarantee eradication of symptoms.55 Up to approximately 40% of people may continue to
experience pain and abdominal symptoms after surgery.56 In particular, marked biliary pain has been
described in 4–9% of people after cholecystectomy, while persistent abdominal pain or non-speciﬁc pain
persists in about 13–37% of people.57–62 A recent systematic review of the literature found that up to
one-third of people suffered continuing pain after cholecystectomy and up to 14% of people experienced
de novo pain.63 Some investigators have also reported a persistent pain similar to that experienced
pre-operatively in about 20% of people with gallstones. In a prospective study conducted in Denmark,
21% of people experienced the same type of pain after surgery.64 Similarly, in a RCT conducted in the
UK, 19% of people complained of biliary pain 5 years after open cholecystectomy.65 No difference
has been observed between open and laparoscopic surgery in terms of persistent pain.66,67 The term
‘post-cholecystectomy syndrome’ is an umbrella term that has been widely used to describe,
though not accurately, the range of symptoms which occur after cholecystectomy.68 The term
‘persistent post-cholecystectomy symptoms’ has been suggested as a more accurate description of these
symptoms.69 These symptoms include biliary and non-biliary abdominal pain, gastrointestinal disorders,
dyspepsia, heartburn, nausea, vomiting, jaundice and cholangitis. Severe symptoms which occur early after
surgery may represent complications of cholecystectomy, whereas those that manifest later (after months
or years) are probably unrelated to cholecystectomy and explained by non-biliary causes. Non-biliary causes
are more likely if the symptoms are similar to those experienced pre-operatively and no stones are found in
the gallbladder. Recent research has suggested that, in some people, functional gastrointestinal disorders3
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4and not gallstone disease may be the cause of persistent post-surgery symptoms.16 Nevertheless, there is
no consistent pathophysiological explanation for persistent post-cholecystectomy symptoms, and in about
5% of people the reason for persistent abdominal pain remains unknown.70Current service provision
Management of disease
Management of gallstone disease may include pharmacological, non-pharmacological and surgical
interventions. Surgery is the deﬁnitive way to treat gallstone disease. Laparoscopic cholecystectomy is
currently preferred over open cholecystectomy for elective surgery in symptomatic gallstones.5,71 In the UK,
people with biliary pain are commonly put on a waiting list and undergo elective surgery several months
after the original clinical diagnosis,72 although early and urgent surgery during the same admission is
becoming more common.
People with symptomatic gallstones who are unﬁt or unwilling to undergo surgery are managed
conservatively or may be offered alternative non-surgical treatments. In particular, conservative
management is a feasible and relatively safe option for pregnant women and elderly people who are less
likely to tolerate surgery.73–75 The terms ‘observation’ and ‘conservative management’ are not clearly
deﬁned in the current literature and appear to be used interchangeably. In general, observation/
conservative management in the context of gallstone disease involves the prescription of analgesics to
relieve the biliary pain. Typical therapy includes narcotic analgesics (e.g. opiates) or non-steroidal
anti-inﬂammatory drugs (e.g. ibuprofen) together with generic lifestyle advice.15,55,76–78 Complicated biliary
pain (i.e. inﬂammation of the gallbladder, namely acute cholecystitis) usually requires additional therapy
with antibiotics.15
Medical therapy for gallstone disease using bile acids, for example ursodeoxycholic acid, to dissolve stones
(especially cholesterol stones) is presently restricted to a small, highly selected group of symptomatic
people for whom a surgical intervention is not recommended and recurrence is likely to have particularly
adverse consequences.15 Novel experimental animal models and preliminary clinical ﬁndings indicate that
future research could focus on the mechanisms of intestinal absorption of cholesterol, on hepatic
cholesterol biosynthesis as well as on the role of gallstones genes.15,79
Other non-pharmacological, non-surgical treatments include dissolution/fragmentation of gallstones using
the cholesterol solvent methyl tert-butyl ether (MTBE) and extracorporeal shock wave lithotripsy (ESWL).
These treatment options are very rarely used in clinical practice because of their potential side effects
(MTBE), high recurrence rate in people with multiple stones (ESWL) and occurrence of transient biliary pain
after successful stone fragmentation (ESWL).5,80,81
The widespread use of laparoscopic cholecystectomy together with the use of imaging techniques for a
more accurate diagnosis of symptomatic gallstone disease has contributed to the decline in non-surgical
medical interventions such as oral bile acids and ESWL.80–82Current service cost
Even though the majority of gallstones are asymptomatic and do not require treatment, gallstone disease
is still the most expensive of the digestive disorders in industrialised societies.83 Considerable resources are
involved in managing people with symptomatic gallstones. The bulk of the economic burden is mainly due
to the costs associated with surgery for the removal of the gallbladder.2,3
According to the NHS 2011/12 tariff for admitted patient care and outpatients procedures, for
laparoscopic cholecystectomy, the day case tariff was £1689, whereas the elective spell tariff was £1370
and the non-elective spell tariff £3197. For open cholecystectomy, the combined day case and spell tariffNIHR Journals Library www.journalslibrary.nihr.ac.uk
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England in 2010–11 to incentivise cholecystectomy on a day-case basis, where clinically appropriate.85Variation in services and/or uncertainty about best practice
In the UK, people with biliary pain are usually put on a waiting list and undergo elective surgery several
months after establishment of a clinical diagnosis of gallstone disease. The waiting time for elective
cholecystectomy varies from hospital to hospital depending on the resources available, but generally lies
between 4 and 12 months (although current clinical targets have led to a shortening of waiting lists).86–89
There is a marked variation between UK health trusts in terms of rates for laparoscopic cholecystectomy.
Approximately half of trusts perform < 5% of cholecystectomies as day cases, with many trusts performing
no day procedures at all.90 The variation is likely to be explained by the local resources available in each
trust and the number of people with symptomatic gallstone disease being treated during the same
emergency admission or electively after undergoing a period of conservative treatment.Relevant national guidelines, including National Service Frameworks
There are no current published national guidelines on the management of gallstone disease.Description of technologies under assessment
Summary of the surgical procedures under assessment
Laparoscopic cholecystectomy is the current standard surgical procedure for the management of gallstone
disease. Since its development in the late 1980s,91 laparoscopic cholecystectomy has increasingly replaced
open cholecystectomy, which remained the gold standard surgical treatment for over 100 years.92
Laparoscopic cholecystectomy has been demonstrated to be a safe and cost-effective procedure with
similar mortality and complications rates to those of open cholecystectomy, but signiﬁcant shorter hospital
stay, quicker recovery93 and lower total cost.94Open cholecystectomy
The ﬁrst open cholecystectomy was performed in 1882 by Carl Langebuch.95 After making an open
incision, the peritoneum covering the triangle of Calot (the area bound by the inferior border of the liver,
cystic duct and common hepatic duct) is dissected, permitting the cystic artery and duct to be identiﬁed
then ligated and divided. The gallbladder can then be dissected from the liver bed (either from the
infundibulum up or from the fundus down). The standard post-operative course is about 5 days
as an inpatient, followed by 3–6 weeks’ convalescence,5 and remains signiﬁcantly longer than
laparoscopic cholecystectomy.
With the widespread use of laparoscopic procedures, there are now limited indications for initiating a
cholecystectomy as an open procedure. Nowadays, the majority of open cholecystectomies consist of
conversions from laparoscopic procedures.96 Conversion to an open procedure may be required because of
the presence of adhesions, difﬁculty in delineating the anatomy or a suspected complication. Conversion is
needed more often in those with prior abdominal surgery, acute cholecystitis or severe/advanced
diseases.25,97 Conversion rates are typically < 10%, including emergency procedures.71,98Laparoscopic cholecystectomy
The majority of people with symptomatic gallstones are candidates for laparoscopic cholecystectomy unless
they are unable to tolerate a general anaesthetic or have comorbidities that preclude surgery.99
During laparoscopic cholecystectomy, the person is placed in the supine position on the operating table
and anaesthetised. Access to the abdomen is gained by either a Veress needle, the open Hasson technique
(direct trocar placement without prior pneumoperitoneum) or the optical view technique (in which the
laparoscope is inside the trocar to allow the abdominal wall layers to be visualised as they are crossed). The
surgeon inﬂates the abdominal cavity with carbon dioxide to create a working space. The camera is placed5
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6through the umbilical port and the abdominal cavity is inspected. Additional ports are inserted to allow the
insertion of instruments. The gallbladder fundus is identiﬁed, grasped and retracted superiorly. With a
second grasper, the gallbladder infundibulum is retracted laterally to expose and open Calot’s triangle. The
cystic duct and the cystic artery are identiﬁed, clipped and divided. The gallbladder is then dissected from
the liver bed and removed via the umbilical port100 or the epigastric port. Laparoscopic surgery requires
meticulous and speciﬁc surgical skills. The procedure usually results in shorter hospital admission and
recovery period than open cholecystectomy (1–2 days in hospital and 1–2 weeks of convalescence).5
The National Institute of Health Consensus Conference statement concluded that laparoscopic
cholecystectomy provides a safe and effective treatment for most people with symptomatic gallstones.5
A Cochrane systematic review comparing open cholecystectomy with laparoscopic cholecystectomy for
symptomatic gallstones93 demonstrated similar mortality and complications rates between the two
procedures but shorter hospital stay, recovery period and lower total cost for laparoscopic surgery.94Single-incision laparoscopic cholecystectomy
Laparoscopic cholecystectomy typically results in three or four small scars caused by the port sites, which is
a marked improvement over the scars left by open procedures. However, there have been recent efforts to
further reduce the potential for scarring by the introduction of the so-called single-incision laparoscopic
procedure. The laparoscope and instruments are both inserted using a single port in the umbilicus, a
location in which a scar can effectively be camouﬂaged.101 From a technical point of view, the
single-incision laparoscopic procedure is very similar to standard laparoscopic cholecystectomy.102
Several recent systematic reviews have compared single-incision and conventional laparoscopic
cholecystectomy. Arezzo and colleagues103 concluded that the single-incision approach was not associated
with more complications than the conventional laparoscopic approach. In addition, no mortality was
reported and conversion rates to open cholecystectomy were similar for both procedures. Wang and
colleagues104 found a higher conversion rate for single-incision cholecystectomy, but did not observe any
difference in complication rates between single-incision and conventional laparoscopic surgery. Antoniou
and colleagues105 observed higher complication rates for people over 45 years of age.
In a recent Cochrane systematic review comparing open cholecystectomy with small incision (< 8 cm)
cholecystectomy for symptomatic gallstones,106 no differences were observed between the two surgical
procedures with regard to complications and mortality rates. Hospital stay was, however, signiﬁcantly
shorter for small incision cholecystectomy.Current usage in the National Health Service
At present, the deﬁnitive treatment choice for gallstone disease is surgery. Cholecystectomy is one of the
most common surgical procedures performed in the UK. About 70,000 cholecystectomies were performed
in England between 2011 and 2012.107 The majority of these surgical procedures were performed after an
elective admission and undertaken laparoscopically.90 Laparoscopic cholecystectomy is technically more
challenging to perform than the traditional open cholecystectomy and the success of the operation
depends on the experience, specialisation and technical skills of the surgeon who performs the procedure.5
In Scotland, the total cholecystectomy rate increased by 18.7% between 1989 and 1993.108 Hospital
Episode Statistics data for England for 2011–12 reported 65,926 admissions for excision of the gallbladder
with a mean waiting time of 81 days. There were 6148 (9%) emergency admissions and 57,920 (88%) on
the waiting list.107
While waiting for surgery, people with symptomatic gallstones are treated conservatively. People who are
unﬁt or unwilling to undergo surgery are managed by means of a ‘wait and see’ therapeutic strategy.
Similarly, people with a single episode of biliary pain and no complications of gallstone disease may be
potential candidates for conservative management, with a reasonable chance to remain symptom free.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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cholecystectomy compared with observation/conservative management for preventing recurrent symptoms
and complications in adults presenting with ﬁrst episode of symptomatic gallstones in secondary care. The
summary care pathway illustrating the decision problem addressed in this assessment is shown in Figure 2.
The care pathway was developed using available published evidence, as well as the outcome of two
advisory meetings with clinical experts convened for the purpose of this assessment. Although the
pathway was primarily designed to guide the main phases of this assessment (e.g. gathering of existing
evidence, development of an economic model), it is broadly consistent with previously published
algorithms for the management of gallstone disease.79 This chapter will consider the main components of
the care pathway for gallstone disease. Speciﬁc information on the population, intervention, comparator
and relevant outcomes considered for this assessment will be provided in Chapter 3 (Methods of the
systematic review of clinical effectiveness).
Population
The population considered for this assessment is adults with symptomatic uncomplicated gallstone disease
(biliary pain or acute cholecystitis) who are examined in a secondary care setting and considered suitable
for cholecystectomy.
Clinical diagnosis of gallstone disease is usually conﬁrmed by imaging and laboratory tests. Transabdominal
ultrasonography is the standard imaging technique for the diagnosis of gallbladder stones. The technique
is accurate, non-invasive and very widely available.7,109,110Intervention: cholecystectomy
Cholecystectomy is the standard treatment for symptomatic gallstone disease and its frequency is
increasing worldwide.50 Nowadays, nearly all cholecystectomies in the UK are performed using a minimally
invasive laparoscopic approach (laparoscopic cholecystectomy).5,111 Any cholecystectomies performed
openly or laparoscopically (or variants thereof) are considered suitable for inclusion.Comparator: observation/conservative management
The comparator intervention considered in this assessment is observation/conservative management.
‘Conservative management’ in the context of gallstone disease typically comprises the prescription of
analgesics/anti-inﬂammatory drugs along with lifestyle advice. People with cholecystitis and signs
of inﬂammation are usually prescribed antibiotics.
‘Delayed surgery’ is not considered a suitable comparator. The focus of recently published randomised
trials and meta-analyses looking at early compared with delayed cholecystectomy (open and laparoscopic)
has been on the optimal timing of surgical intervention as well as operative outcomes (in a patient
population scheduled to receive surgery) rather than on the necessity of cholecystectomy in people with
uncomplicated symptomatic gallstones presenting to secondary care.7
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FIGURE 2 Flow chart of the clinical decision-making process for people with symptomatic uncomplicated
gallstone disease.
DEFINITION OF THE DECISION PROBLEM
8Overall aims and objectives of assessmentThe aim of this assessment was to evaluate the clinical effectiveness and cost-effectiveness of
cholecystectomy compared with observation/conservative management for preventing recurrent symptoms
and complications in adults presenting with symptomatic gallstones (biliary pain or cholecystitis) in
secondary care for the ﬁrst time.
The speciﬁc objectives of this assessment will help to facilitate decision-making on the most appropriate
treatments for people suffering from uncomplicated symptomatic gallstone disease (biliary pain or
cholecystitis) by:
l conducting a systematic review of the evidence available on the clinical effectiveness of
cholecystectomy compared with observation/conservative management
l conducting a systematic review of the evidence available on the cost-effectiveness of cholecystectomy
compared with observation/conservative management
l developing an economic model to compare the cost-effectiveness cholecystectomy with that of
observation/conservative management
l determining which management options are most likely to be efﬁcient for implementation into the
UK NHS
l identifying and prioritising future research.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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clinical effectivenessThe methods for this assessment were pre-speciﬁed in a protocol.
Identiﬁcation of studiesComprehensive literature searches were conducted to identify reports of studies on the clinical
effectiveness and/or cost-effectiveness of cholecystectomy compared with non-surgical interventions for
the management of people with symptomatic gallstone disease (biliary pain or acute cholecystitis). Highly
sensitive search strategies were designed, including appropriate subject headings and free-text terms for
the interventions under consideration and relevant study designs. No language restrictions were imposed
on the literature searches. Searches were restricted to 1980 onwards, to mirror the use of surgical
techniques currently available in clinical practice as well as the introduction of novel interventions for the
management of symptomatic gallstones.
Databases searched were MEDLINE (1980 to 9 September 2012), MEDLINE In-Process & Other
Non-Indexed Citations (10 September 2012), EMBASE (1980 to 10 September 2012), the Science Citation
Index (1980 to 12 September 2012), Bioscience Information Service (BIOSIS; 1980 to 12 September 2012)
and the Cochrane Central Register of Controlled Trials (date of inception to Issue 9, 2012). Reports of
relevant evidence syntheses were also sought from the Cochrane Database of Systematic Reviews and the
Database of Abstracts of Review of Effects.
The World Health Organization International Clinical Trials Registry (date of inception to September 2012),
Current Controlled Trials (date of inception to September 2012), Clinical Trials (date of inception to
September 2012) and the National Institute for Health Research Portfolio (date of inception to September
2012) were also searched to identify potential relevant ongoing studies. Conference proceedings from
2011 and 2012 of key organisations such as the Association of Upper Gastrointestinal Surgeons of Great
Britain and Ireland, the Association of Laparoscopic Surgeons of Great Britain and Ireland and the British
Society of Gastroenterology were screened for further relevant reports. The reference lists of all included
studies were perused to identify additional potentially relevant reports. Full details of the search strategy
are reported in Appendix 1.Inclusion and exclusion criteria
Types of studies
For assessing the clinical effectiveness of cholecystectomy compared with observation/conservative
management in people with biliary pain or acute cholecystitis, the following types of study design were
deemed suitable for inclusion:
l RCTs which randomised people to either cholecystectomy (open or laparoscopic) or observation/
conservative management, irrespective of study language, blinding and publication status
l non-randomised comparative studies in which people received either cholecystectomy (open or
laparoscopic) or observation/conservative management.9
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METHODS OF THE SYSTEMATIC REVIEW OF CLINICAL EFFECTIVENESS
10The following types of report were excluded:
l reviews, editorials and opinions
l case series and case reports
l reports published in non-English languages for which a translation could not be organised.Types of participants
Adults (18 years and older or ‘adults’ as deﬁned by the triallists) with symptomatic gallstone disease
(biliary pain or acute cholecystitis) being considered for cholecystectomy in a secondary care setting for the
ﬁrst time. Gallstone-related disease needed to be conﬁrmed by ultrasonography. For the purpose of this
assessment, ‘ﬁrst episode of symptomatic gallstones’ was deﬁned as the ﬁrst instance in which the patient
presented to secondary care attention (with the possibility of receiving surgical treatment) even though the
clinical history documented previous clinical symptoms or pain attacks. This criterion was later relaxed to
allow inclusion of studies in which up to 25% of participants had previously presented to secondary care
for symptomatic gallstones. First episode was assumed unless studies explicitly described cases as recurrent.
Eligibility for cholecystectomy, if not explicitly reported, was assumed in RCTs whereas non-randomised
studies were assessed on an individual basis on this criterion. An accepted deﬁnition of ‘acute cholecystitis’
is based on a combination of relevant clinical symptoms (e.g. pain localised to the right upper quadrant of
the abdomen; temperature exceeding 37.5 °C, leucocytosis greater than 10 × 109/l, increased C-reactive
protein level) and ultrasonographic evidence of gallstones.
People with acute severe cholecystitis (e.g. obstruction of the cystic duct or neck of the gallbladder by
gallstones) and/or cholangitis (inﬂammation, usually infection, of a bile duct) or pancreatitis were not
considered suitable for inclusion, as they normally require urgent or emergency intervention. Similarly,
people with symptomatic gallstones complicated by severe concomitant diseases, critically ill people, and/or
people who were judged to be unﬁt or unsuitable for surgery (e.g. pregnant women) were not considered
within the scope of this review.
Therefore, for those with acute cholecystitis, we included any study population presenting with acute,
uncomplicated, cholecystitis.Intervention
The intervention considered was surgical removal of the gallbladder (laparoscopic or open cholecystectomy).Comparator interventions
The comparator interventions considered were observation (watchful waiting) and/or conservative
treatment. Conservative treatment refers here to a course of analgesics/anti-inﬂammatory drugs
accompanied by lifestyle advice. People with cholecystitis and signs of inﬂammation may also be
prescribed antibiotics.Types of outcomes
The following types of outcome measure were considered:
l disease-related morbidity
¢ recurrence of symptoms
¢ complications (e.g. pancreatitis)
¢ number of visits to primary care settings or hospital emergency department
¢ analgesic requirements
¢ need for surgical, endoscopic or radiological intervention
¢ need for further medical intervention
¢ mortalityNIHR Journals Library www.journalslibrary.nihr.ac.uk
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¢ bile duct injury
¢ infection/bleeding
¢ reoperation rate
¢ diarrhoea
¢ recurrent pain
¢ mortality
l patient-driven outcomes
¢ generic and disease-speciﬁc quality of life (QoL; as deﬁned by the studies’ authors)
l cost of initial and any subsequent treatments.Data extraction strategyOne reviewer (MC) screened all titles and, when available, abstracts of all citations identiﬁed by the search
strategies. All potentially relevant reports were retrieved in full and assessed independently by two
reviewers. Any disagreements were resolved by consensus or referred to a third party. A sample full-text
screening form is presented in Appendix 2.
A data extraction form was designed speciﬁcally for the purpose of this assessment to collect data from
included studies. Two independent reviewers (MC and MB) extracted details of study design, characteristics
of participants, characteristics of interventions and outcome measures. Any disagreements were resolved
by consensus. A sample data extraction form is presented in Appendix 3.Critical appraisal strategyIncluded RCTs were assessed by means of the Cochrane Collaboration’s risk of bias tool.112 A sample form
is presented in Appendix 4. Two reviewers (MC and MB) independently assessed the risk of bias within
each included trial based on the following domains: sequence generation, allocation concealment,
blinding, incomplete outcome data and selective outcome reporting. Individual outcomes were categorised
as high risk of bias, low risk of bias or unclear risk of bias. Any disagreements between reviewers were
resolved by consensus.Methods of data synthesisResults of each included study were tabulated for all outcomes with means reported for continuous
outcomes and proportions for dichotomous outcomes. Where the same outcome was assessed by more
than one included study, a quantitative synthesis of results was carried out using Review Manager
(RevMan) computer program (version 5.2. Copenhagen, Denmark: The Nordic Cochrane Centre, The
Cochrane Collaboration, 2012). Heterogeneity between studies was assessed by visual inspection of forest
plots and from Mantel–Haenszel chi-squared and I2 tests. Meta-analyses using the Mantel–Haenszel
method were carried out to estimate risk ratios pooled across studies, with corresponding 95% conﬁdence
intervals (CIs). Where there was unacceptable heterogeneity between studies, random-effects models were
used, otherwise ﬁxed-effects models were applied.11
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DOI: 10.3310/hta18550 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 55Chapter 4 Clinical effectiveness of
cholecystectomy compared with observation/
conservative managementQuantity of research available
Number and type of studies included
The primary literature searches identiﬁed 6779 potentially relevant citations. Seventy-seven reports were
selected for full-text assessment. Seventy-one reports were subsequently excluded (see Appendix 5). Two
RCTs published in six reports were included in this assessment.46,55,77,78,113,114 No eligible non-randomised
comparative studies were identiﬁed by the literature searches. A ﬂow diagram of the screening process is
outlined in Figure 3.
Appendix 5 provides the bibliographic details of the included and excluded studies.Number and type of studies excluded
A list of the 71 full-text papers that were excluded along with the reasons for their exclusion is given in
Appendix 5. These reports were excluded because they failed to meet one or more of the inclusion criteria
in terms of the type of study, participants, intervention/comparator or outcomes reported.Characteristics of the included studies
The search identiﬁed two randomised trials, Schmidt et al.113 and Schmidt et al.,46 published in full in six
reports.46,55,77,78,113,114 Participants were enrolled consecutively in both trials and data were collected
prospectively. Both trials were conducted in Norway.
Table 1 presents the demographic information from the studies. The two trials included a total of
201 participants at enrolment. There were no dropouts during the study period and all 201 randomised
participants were included in the statistical analyses. Participants’ diagnosis was uncomplicated
symptomatic gallstones (biliary pain only) in Schmidt et al.113 and acute cholecystitis in Schmidt et al.46
In total, 149 women and 52 men were assessed. Of these, 72 women and 27 men were randomised to
surgery, while 77 women and 25 men were randomised to observation. Median age was 50 years
(range 20–79 years) in Schmidt et al.113 and 58 years (range 27–77 years) in Schmidt et al.46 Both trials
enrolled some participants who had previously presented to secondary care for gallstone disease:
30 participants (22%) in Schmidt et al.113 and 11 participants (17%) in Schmidt et al.46 Both trials also
reported the number of participants with concomitant diseases, speciﬁcally heart disease, diabetes and/or
obstructive lung disease, in total 16 participants (12%) in Schmidt et al.113 and 12 participants (19%) in
Schmidt et al.46 Baseline QoL, as assessed by the psychological general well being index (PGWB),
Nottingham Health Proﬁle (NHP) part II, pain score and Visual Analogue Pain Score (VAPS), were
comparable across the studies. The mean follow-up was 14 years (range 13–16 years) for both trials.
Similarly, the median follow-up was 14 years in Schmidt et al.46
Table 2 presents the key features of the two included studies.13
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Studies identified from primary
searches
(n = 6779) 
Excluded
(n = 6622)
Excluded
(n = 71)
1 no relevant outcomes 
13 ineligible study design 
17 ineligible population 
33 ineligible comparator 
7 unavailable 
Included
(n = 2; 6 reports)
Selected for full-text screening
(n = 77) 
Studies identified from other sources
(n = 1) 
Retrieved for background
(n = 48)
Retrieved for cost-effectiveness
review
(n = 33)
FIGURE 3 Flow chart for the identification and selection of studies.
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TABLE 1 Demographic information of included studies
Characteristics
Schmidt et al. 2011113 Schmidt et al. 201146
Surgery
(n = 68)
Observation
(n = 69)
Surgery
(n = 31)
Observation
(n = 33)
Sex
Men (%) 13 (19) 12 (17) 14 (45) 13 (39)
Women (%) 55 (81) 57 (83) 17 (55) 20 (61)
Age (years)
Men (median, range) 52 (27–74) 60 (30–79) 64 (41–77) 64 (29–73)
Women (median, range) 52 (20–77) 48 (22–75) 58 (27–77) 47 (29–71)
Age overall (median, range) 50 (20–79) 58 (27–77)
Diagnosis
Uncomplicated symptomatic
gallstones (biliary pain only) Acute cholecystitis
Previous gallstones attacks (%) 64 (94) 63 (91) NR NR
Previous hospitalisation for gallstone disease (%) 14 (21) 16 (23) 11 (17)
Concomitant disease (heart disease/diabetes/
obstructive lung disease) (%)
16 (12) 12 (19)
Baseline QoL
PGWB score (higher score better) 93.7 (n = 63) 95.2 (n = 67) 88.1 (n = 31) 94.2 (n = 31)
NHP score (lower score better) 2.0 (n = 50) 1.8 (n = 53) 2.2 (n = 28) 2.0 (n = 29)
Pain score (lower score better) 6.3 (n = 67) 6.7 (n = 66) 8.1 (n = 31) 6.6 (n = 33)
VAPS (lower score better) 47.2 (n = 67) 48.1 (n = 65) 57.7 (n = 31) 57.1 (n = 31)
NHP, Nottingham Health Proﬁle part II, range 0–7; pain score, encompasses intensity and duration of pain in the last week;
frequency of pain and analgesic use in last 6 months, range 0–16; NR, not reported; PGWB, Psychological General Well
Being index, range 22–132; VAPS, Visual Analogue Pain Score, people mark a non-graded 100-mm line ranging from no
pain to unbearable pain to reﬂect intensity of pain during previous week.
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18Risk of bias of the included studies
The two published trials were assessed using The Cochrane Collaboration’s risk of bias tool.112 Tables 3
and 4 and Figures 4 and 5 present the summary ﬁndings of this assessment. Both trials were judged to be
at low risk for all domains assessed by the tool.TABLE 4 Risk of bias table (Schmidt et al. 2011)46
Schmidt et al. 2011 Judgement Support for judgement
Random sequence generation (selection bias) Low Randomisation was by a computer program
Allocation concealment (selection bias) Low Brown, opaque, sealed envelopes were used to
conceal the allocation
Blinding of participants and personnel
(performance bias)
Low Blinding was not an option, as the intervention being
delivered would have been obvious to all concerned
Blinding of outcome assessment (detection bias) Low Blinding was not possible as outcomes were either
participants’ self-reports or retrieved from medical
records
Incomplete outcome data (attrition bias) Low Details of exclusions and attrition were fully reported.
All participants were included in the analysis
Selective reporting (attrition bias) Low All stated outcomes were reported
Other sources of bias (reporting bias) Low No other potential sources of bias were identiﬁed
TABLE 3 Risk of bias table (Schmidt et al. 2011)113
Schmidt et al. 2011 Judgement Support for judgement
Random sequence generation (selection bias) Low Randomisation was by a computer program
Allocation concealment (selection bias) Low Brown, opaque, sealed envelopes were used to
conceal the allocation
Blinding of participants and personnel
(performance bias)
Low Blinding was not an option, as the intervention being
delivered would have been obvious to all concerned
Blinding of outcome assessment (detection bias) Low Blinding was not possible as outcomes were either
participants’ self-reports or retrieved from medical
records
Incomplete outcome data (attrition bias) Low Details of exclusions and attrition were fully reported.
All participants were included in the analysis
Selective reporting (attrition bias) Low All stated outcomes were reported
Other sources of bias (reporting bias) Low No other potential sources of bias were identiﬁed
Random sequence generation (selection bias)
Allocation concealment (selection bias)
Blinding of participants and personnel (performance bias)
Blinding of outcome assessment (detection bias)
Incomplete outcome data (attrition bias)
Selective reporting (reporting bias)
Other bias
0% 25% 50% 75% 100%
Low risk of bias
Unclear risk of bias
High risk of bias
FIGURE 4 Risk of bias graph for both included studies.
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FIGURE 5 Risk of bias summary figure.
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A detailed description of the main clinical ﬁndings of Schmidt et al.113 and Schmidt et al.46 is given
in Table 5. Meta-analyses of relevant clinical results were performed, when possible. Fixed-effects models
were used only where there were acceptable levels of homogeneity between the studies (as identiﬁed
by visual inspection of forest plots and from Mantel–Haenszel chi-squared and I2 tests), otherwise
random-effects models were preferred.
Overview of outcomes included in meta-analysesNumber of participants undergoing surgery (14 years)
A total of 46 out of 102 (45%) participants randomised to observation and 87 out of 99 (88%)
participants randomised to surgery underwent cholecystectomy (Figure 6). This was a statistically signiﬁcant
difference between the groups (risk ratio = 0.50; 95% CI 0.34 to 0.73; p = 0.0004).
Pain attacks (14 years)
A total of 26 out of 102 (25%) participants randomised to observation and 12 out of 99 (12%)
participants randomised to surgery experienced pain attacks (Figure 7). The difference between the groups
was not statistically signiﬁcant (risk ratio = 1.62; 95% CI 0.43 to 6.17; p = 0.48).
In general, pain attacks were reported more frequently in participants with uncomplicated symptomatic
gallstone disease managed conservatively. One-third (33%) of participants with uncomplicated symptomatic
gallstones (biliary pain only) randomised to observation experienced pain attacks after randomisation
compared with only 9% of participants with acute cholecystitis. It is worth pointing out that a similar
proportion of participants randomised to surgery experienced post-randomisation pain attacks across the
groups (12%, Schmidt et al.;113 13%, Schmidt et al.46). Signiﬁcantly more participants with uncomplicated
symptomatic gallstones (biliary pain only) randomised to observation experienced pain attacks than those
randomised to surgery (χ2 = 9.10; p = 0.0026), whereas no difference was observed between intervention
groups within participants with an initial diagnosis of acute cholecystitis (χ2 = 0.24; p = 0.6253).19
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Brazzelli et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
TA
B
LE
5
Fi
n
d
in
g
s
o
f
in
cl
u
d
ed
st
u
d
ie
s
O
u
tc
o
m
es
an
d
ad
ve
rs
e
ev
en
ts
Sc
h
m
id
t
e
t
a
l.
20
11
1
1
3
(n
=
13
7)
Sc
h
m
id
t
e
t
a
l.
20
11
4
6
(n
=
64
)
O
b
se
rv
at
io
n
(n
=
69
)
Su
rg
er
y
(n
=
68
)
O
b
se
rv
at
io
n
(n
=
33
)
Su
rg
er
y
(n
=
31
)
5
ye
ar
s
14
ye
ar
s
5
ye
ar
s
14
ye
ar
s
5
ye
ar
s
14
ye
ar
s
5
ye
ar
s
14
ye
ar
s
N
o.
pa
tie
nt
s
un
de
rg
oi
ng
su
rg
er
y
(%
)
35
(5
1)
35
(5
1)
60
(8
8)
60
(8
8)
10
(3
0)
11
(3
3)
27
(8
7)
27
(8
7)
Pa
in
at
ta
ck
sa
N
R
23
(3
3)
N
R
8
(1
2)
N
R
3
(9
)
N
R
4
(1
3)
G
al
ls
to
ne
-r
el
at
ed
co
m
pl
ic
at
io
ns
a
(%
)
3
(4
)
3
(4
)
1
(1
)
1
(1
)
13
(3
9)
11
(3
3)
3
(1
0)
1(
3%
)
A
cu
te
ch
ol
ec
ys
tit
is
1
1
0
0
9
8
1
0
C
BD
st
on
es
2
1
0
0
4b
3
1c
1
A
cu
te
pa
nc
re
at
iti
s
0
1
1
1
0
0
1
0
Su
rg
er
y-
re
la
te
d
co
m
pl
ic
at
io
ns
(%
)
5
(7
)
N
R
10
(1
5)
N
R
2
(6
)
N
R
9
(2
9)
N
R
In
tr
a-
ab
do
m
in
al
in
fe
ct
io
n/
bi
le
le
ak
ag
e
3
2
1
1
W
ou
nd
in
fe
ct
io
n/
de
hi
sc
en
ce
1
1
0
0
Bi
le
du
ct
in
ju
ry
0
0
0
1
Re
op
er
at
io
n
1
1
0
0
M
in
or
co
m
pl
ic
at
io
ns
0
6
1
7
A
dm
is
si
on
du
e
to
ga
lls
to
ne
-r
el
at
ed
pa
in
a
(%
)
12
(1
7)
N
R
2
(3
)
N
R
4
(1
2)
N
R
3
(1
0)
N
R
M
or
ta
lit
y
(%
)
N
Rd
8
(1
2)
N
Rd
11
(1
6)
0
(0
)
8
(2
4)
4
(1
3)
10
(3
2)
Fu
rt
he
r
su
rg
ic
al
in
te
rv
en
tio
n
ne
ed
ed
N
R
N
R
N
R
4
(6
)
ER
C
P
(C
BD
st
on
es
in
on
e)
N
R
N
R
N
R
N
R
M
ed
ia
n
tim
e
to
su
rg
er
y
(m
on
th
s)
fr
om
ra
nd
om
is
at
io
n
(r
an
ge
)
N
R
28
N
R
3
(0
–
16
8)
N
R
N
R
3.
6
(0
.5
–
12
.8
)
4
(1
–
13
)
CLINICAL EFFECTIVENESS OF CHOLECYSTECTOMY COMPARED WITH OBSERVATION/CONSERVATIVE MANAGEMENT
20
NIHR Journals Library www.journalslibrary.nihr.ac.uk
O
u
tc
o
m
es
an
d
ad
ve
rs
e
ev
en
ts
Sc
h
m
id
t
e
t
a
l.
20
11
1
1
3
(n
=
13
7)
Sc
h
m
id
t
e
t
a
l.
20
11
4
6
(n
=
64
)
O
b
se
rv
at
io
n
(n
=
69
)
Su
rg
er
y
(n
=
68
)
O
b
se
rv
at
io
n
(n
=
33
)
Su
rg
er
y
(n
=
31
)
5
ye
ar
s
14
ye
ar
s
5
ye
ar
s
14
ye
ar
s
5
ye
ar
s
14
ye
ar
s
5
ye
ar
s
14
ye
ar
s
Q
o
L
(m
e
a
n
v
a
lu
e
s)
–
6
m
o
n
th
s
PG
W
B
sc
or
e
(h
ig
he
r
sc
or
e
be
tt
er
)
99
.9
(n
=
59
)
N
R
10
3.
3
(n
=
54
)
N
R
11
0.
2
(n
=
33
)
N
R
10
6.
2
(n
=
25
)
N
R
N
H
P
sc
or
e
(lo
w
er
sc
or
e
be
tt
er
)
1.
6
(n
=
46
)
1.
1
(n
=
43
)
1.
1
(n
=
25
)
1.
2
(n
=
18
)
Pa
in
sc
or
e
(lo
w
er
sc
or
e
be
tt
er
)
4.
1
(n
=
63
)
2.
2
(n
=
57
)
2.
1
(n
=
31
)
2.
0
(n
=
27
)
V
A
PS
(lo
w
er
sc
or
e
be
tt
er
)
14
.7
(n
=
61
)
9.
4
(n
=
57
)
8.
1
(n
=
30
)
5.
4
(n
=
24
)
Q
o
L
(m
e
a
n
v
a
lu
e
s)
–
1
2
m
o
n
th
s
PG
W
B
sc
or
e
(h
ig
he
r
sc
or
e
be
tt
er
)
10
1.
8
(n
=
60
)
N
R
10
2.
3
(n
=
57
)
N
R
10
3.
1
(n
=
32
)
N
R
10
3.
2
(n
=
25
)
N
R
N
H
P
sc
or
e
(lo
w
er
sc
or
e
be
tt
er
)
1.
6
(n
=
46
)
1.
0
(n
=
43
)
0.
9
(n
=
22
)
1.
2
(n
=
18
)
Pa
in
sc
or
e
(lo
w
er
sc
or
e
be
tt
er
)
3.
7
(n
=
61
)
2.
3
(n
=
58
)
3.
1
(n
=
32
)
2.
4
(n
=
25
)
V
A
PS
(lo
w
er
sc
or
e
be
tt
er
)
15
.7
(n
=
60
)
7.
0
(n
=
55
)
15
.1
(n
=
31
)
9.
9
(n
=
24
)
Q
o
L
(m
e
a
n
v
a
lu
e
s)
–
6
0
m
o
n
th
s
PG
W
B
sc
or
e
(h
ig
he
r
sc
or
e
be
tt
er
)
10
4.
1
(n
=
55
)
N
R
10
1.
6
(n
=
56
)
N
R
11
2.
0
(n
=
30
)
N
R
10
2.
5
(n
=
25
)
N
R
N
H
P
sc
or
e
(lo
w
er
sc
or
e
be
tt
er
)
1.
3
(n
=
47
)
1.
9
(n
=
52
)
0.
7
(n
=
27
)
1.
4
(n
=
23
)
Pa
in
sc
or
e
(lo
w
er
sc
or
e
be
tt
er
)
2.
4
(n
=
56
)
2.
0
(n
=
56
)
1.
3
(n
=
31
)
2.
6
(n
=
24
)
V
A
PS
(lo
w
er
sc
or
e
be
tt
er
)
11
.5
(n
=
56
)
5.
5
(n
=
55
)
6.
2
(n
=
31
)
11
.3
(n
=
24
)
ER
C
P,
en
d
o
sc
o
p
ic
re
tr
o
g
ra
d
e
ch
o
la
n
gi
o
p
an
cr
ea
to
g
ra
p
hy
;
N
H
P,
N
o
tt
in
g
h
am
H
ea
lth
Pr
o
ﬁ
le
p
ar
t
II,
ra
n
g
e
0
–
7
(lo
w
er
sc
o
re
b
et
te
r)
;
N
R
,
n
o
t
re
p
o
rt
ed
;
Pa
in
sc
o
re
,
en
co
m
p
as
se
s
in
te
n
si
ty
an
d
du
ra
tio
n
of
pa
in
in
th
e
la
st
w
ee
k,
an
d
fr
eq
ue
nc
y
of
pa
in
an
d
an
al
ge
si
c
us
e
in
la
st
6
m
on
th
s,
ra
ng
e
0–
16
(lo
w
er
sc
or
e
be
tt
er
);
PG
W
B,
Ps
yc
ho
lo
gi
ca
lG
en
er
al
W
el
lB
ei
ng
in
de
x,
ra
ng
e
22
–
13
2
(h
ig
he
r
sc
or
e
be
tt
er
);
V
A
PS
,V
is
ua
lA
na
lo
gu
e
Pa
in
Sc
or
e,
pa
tie
nt
s
m
ar
k
a
no
n-
gr
ad
ed
10
0-
m
m
lin
e
ra
ng
in
g
fr
om
no
pa
in
to
un
be
ar
ab
le
pa
in
to
re
ﬂ
ec
t
in
te
ns
ity
of
pa
in
du
rin
g
pr
ev
io
us
w
ee
k
(lo
w
er
sc
or
e
be
tt
er
).
a
Fo
r
th
e
14
-y
ea
r
da
ta
,
ev
en
ts
th
at
to
ok
pl
ac
e
be
fo
re
su
rg
er
y
in
th
e
gr
ou
p
ra
nd
om
is
ed
to
ch
ol
ec
ys
te
ct
om
y
w
er
e
no
t
in
cl
ud
ed
,
un
le
ss
as
a
re
su
lt
of
dr
op
ou
t
fr
om
su
rg
er
y.
b
n
=
1
la
te
co
m
pl
ic
at
io
n
af
te
r
su
rg
er
y.
c
La
te
co
m
pl
ic
at
io
n
af
te
r
su
rg
er
y.
d
To
ta
l8
ou
t
of
13
7
ra
nd
om
is
ed
pa
rt
ic
ip
an
ts
ha
d
di
ed
.
DOI: 10.3310/hta18550 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 55
21
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Brazzelli et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
Sc
h
m
id
t 
20
11
11
3
Sc
h
m
id
t 
20
11
46
35 11
69 33
60 27
68 31
64
.4
%
35
.6
%
To
ta
l (
95
%
 C
l)
10
2
99
10
0.
0%
0.
57
 (
0.
45
 t
o
 0
.7
4)
0.
38
 (
0.
23
 t
o
 0
.6
3)
0.
50
 (
0.
34
 t
o
 0
.7
3)
To
ta
l e
ve
n
ts
H
et
er
o
g
en
ei
ty
: τ
 =
 0
.0
5;
 χ
2  =
 2
.1
1,
 d
f =
 1
 (
 p
 =
 0
.1
5)
; I
 2  =
 5
3%
Te
st
 f
o
r 
o
ve
ra
ll 
ef
fe
ct
: z
 =
 3
.5
2 
( p
 =
 0
.0
00
4)
46
87
St
u
d
y 
o
r 
su
b
g
ro
u
p
Ev
en
ts
To
ta
l
Ev
en
ts
To
ta
l
W
ei
g
h
t
O
b
se
rv
at
io
n
Su
rg
er
y
R
is
k 
ra
ti
o
M
–H
, r
an
d
o
m
 (
95
%
 C
I)
R
is
k 
ra
ti
o
M
–H
, r
an
d
o
m
 (
95
%
 C
I)
0.
01
0.
10
1
10
10
0
Fa
vo
u
rs
 o
b
se
rv
at
io
n
Fa
vo
u
rs
 s
u
r g
er
y
FI
G
U
R
E
6
Fo
re
st
p
lo
t
o
f
p
ar
ti
ci
p
an
ts
h
av
in
g
su
rg
er
y
(1
4
ye
ar
s)
.
Sc
h
m
id
t 
20
11
11
3
Sc
h
m
id
t 
20
11
46
23 3
69 33
8 4
68 31
59
.8
%
40
.2
%
To
ta
l (
95
%
 C
l)
10
2
99
10
0.
0%
2.
83
 (
1.
36
 t
o
 5
.8
9)
0.
70
 (
0.
17
 t
o
 2
.9
0)
1.
62
 (
0.
43
 t
o
 6
.1
7)
To
ta
l e
ve
n
ts
H
et
er
o
g
en
ei
ty
: τ
 =
 0
.6
4;
 χ
2  =
 2
.9
3,
 d
f =
 1
 (
 p
 =
 0
.0
9)
; I
 2  =
 6
6%
Te
st
 f
o
r 
o
ve
ra
ll 
ef
fe
ct
: z
 =
 0
.7
1 
( p
 =
 0
.4
8)26
12
St
u
d
y 
o
r 
su
b
g
ro
u
p
Ev
en
ts
To
ta
l
Ev
en
ts
To
ta
l
W
ei
g
h
t
O
b
se
rv
at
io
n
Su
rg
er
y
R
is
k 
ra
ti
o
M
–H
, r
an
d
o
m
 (
95
%
 C
I)
R
is
k 
ra
ti
o
M
–H
, r
an
d
o
m
 (
95
%
 C
I)
0.
01
0.
10
1
10
10
0
Fa
vo
u
rs
 o
b
se
rv
at
io
n
Fa
vo
u
rs
 s
u
rg
er
y
FI
G
U
R
E
7
Fo
re
st
p
lo
t
o
f
p
ai
n
at
ta
ck
s
(1
4
ye
ar
s)
.
CLINICAL EFFECTIVENESS OF CHOLECYSTECTOMY COMPARED WITH OBSERVATION/CONSERVATIVE MANAGEMENT
22
NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18550 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 55Gallstone-related complications: total (14 years)
Signiﬁcantly more participants randomised to observation (14/102; 14%) than those randomised to
surgery (2/99; 2%) experienced any of the speciﬁed gallstone-related complications (risk ratio = 6.69;
95% CI 1.57 to 28.51; p = 0.01) (Figure 8).
Details of participants with acute cholecystitis, CBD stones and acute pancreatitis are presented below.Gallstone-related complications: acute cholecystitis (14 years)
Participants randomised to observation were more likely to suffer from acute cholecystitis as a complication
(Figure 9). Nine of the 102 (9%) participants randomised to observation and none of the 99 (0%)
participants randomised to surgery experienced acute cholecystitis as a complication. The difference
between intervention groups was statistically signiﬁcant (risk ratio = 9.55; 95% CI 1.25 to 73.27; p = 0.03).
It is worth noting that, among those treated conservatively, new complicated events occurred more
frequently in those in whom the initial diagnosis was acute cholecystitis than in those initially diagnosed as
having uncomplicated symptomatic gallstones (biliary pain only).Gallstone-related complications: common bile duct stones (14 years)
Few participants in both intervention groups suffered from CBD stones at the 14-year follow-up
assessment (Figure 10). Four of the 102 (4%) participants randomised to observation and 1 of the 99 (1%)
participants randomised to surgery experienced CBD stones. The difference between the groups was not
statistically signiﬁcant (risk ratio = 2.86; 95% CI 0.47 to 17.59; p = 0.26).
Gallstone-related complications: acute pancreatitis (14 years)
The risk of experiencing acute pancreatitis was the same in both intervention groups (Figure 11). One of
the 102 (1%) participants randomised to observation and 1 of the 99 (1%) participants randomised to
surgery experienced acute pancreatitis (risk ratio = 0.99; 95% CI 0.06 to 15.44; p = 0.99). Both events
occurred in participants with uncomplicated symptomatic gallstones (biliary pain only) whereas participants
with acute cholecystitis did not experience this complication.
Surgery-related complications: total (5 years)
As expected, the risk of surgery-related complications was signiﬁcantly lower in the observation group
(Figure 12). In total, 7 out of 102 (7%) participants randomised to observation and 19 out of 99 (19%)
participants randomised to surgery experienced surgery-related complications (risk ratio = 0.36; 95% CI
0.16 to 0.81; p = 0.01).
Further details of individual surgery-related complications are presented below.Surgery-related complications: intra-abdominal infection/bile leakage
(5 years)
The risk of suffering from intra-abdominal infection/bile leakage was similar in both intervention groups
(Figure 13). A total of 4 out of 102 (4%) participants randomised to observation and 3 out of 99 (3%)
participants randomised to surgery experienced intra-abdominal infection or bile leakage (risk ratio = 1.30;
95% CI 0.30 to 5.63; p = 0.73). Five of the seven events were experienced by participants originally
diagnosed with uncomplicated symptomatic gallstones (biliary pain only).
Surgery-related complications: wound infection/dehiscence (5 years)
The number of participants who suffered from wound infection/dehiscence after surgery was the same in
both intervention groups (Figure 14). One of the 102 (1%) participants randomised to observation and
1 of the 99 (1%) participants randomised to surgery experienced wound infection or dehiscence (risk
ratio = 0.99; 95% CI 0.06 to 15.44; p = 0.99). Both events occurred in participants diagnosed with
uncomplicated symptomatic gallstones (biliary pain only) whereas no participants diagnosed with acute
cholecystitis experienced this complication.23
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DOI: 10.3310/hta18550 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 55Surgery-related complications: bile duct injury
Figure 15 shows that only one participant randomised to surgery suffered from bile duct injury within
5 years (risk ratio = 0.31; 95% CI 0.01 to 7.42; p = 0.47).
Surgery-related complications: reoperation (5 years)
The number of participants who required reoperation was the same in both intervention groups (Figure 16).
One of the 102 (1%) participants randomised to observation and 1 of the 99 (1%) participants randomised
to surgery underwent reoperation (risk ratio = 0.99; 95% CI 0.06 to 15.44; p = 0.99). Both participants who
underwent reoperation were originally diagnosed with uncomplicated gallstones (biliary pain only).
Surgery-related complications: minor complications (5 years)
Signiﬁcantly fewer participants randomised to observation experienced minor complications (1/102; 1%)
than participants randomised to surgery (13/99; 13%) (risk ratio = 0.11; 95% CI 0.02 to 0.56; p = 0.008)
(Figure 17). A slightly larger proportion of participants originally diagnosed with acute cholecystitis
experienced minor complications (8/64; 13%) than participants with uncomplicated symptomatic gallstones
(biliary pain only) (6/137; 4%). The nature of minor complications was not described in the included trials.
Admission due to gallstone-related pain (5 years)
A total of 16 out of 102 (16%) participants randomised to observation and 5 out of 99 (5%) participants
randomised to surgery were admitted to hospital because of gallstone-related pain (Figure 18). There was
no statistically signiﬁcant difference between the intervention groups at the 5-year follow-up
(risk ratio = 2.69; 95% CI 0.57 to 12.68; p = 0.21).For both uncomplicated symptomatic gallstones (biliary pain only) and acute cholecystitis groups,
more participants randomised to observation than to surgery were subsequently admitted to hospital for
gallstone-related pain (12 vs. 2 people with biliary pain and 4 vs. 3 people with acute cholecystitis). It is
worth noting that the difference between intervention groups was statistically signiﬁcant for participants
with uncomplicated symptomatic gallstones (biliary pain only) (χ2 = 7.79; p = 0.0052) but not for those with
acute cholecystitis (χ2 = 0.10; p = 0.7542).Mortality rate (14 years)
Schmidt et al.113 reported that a total of 8 out of 137 participants with uncomplicated symptomatic
gallstones (biliary pain only) had died by the 5-year follow-up, but they did not provide separate data for
each intervention group. At the 14-year follow-up assessment, 8 out of 68 participants randomised to
surgery and 11 out of 69 participants randomised to observation had died.
Schmidt et al.46 reported that 4 out of 31 participants with acute cholecystitis who were randomised to
surgery had died by the 5-year follow-up, whereas no deaths were observed among participants
randomised to observation. By the 14-year follow-up, 8 out of 31 participants randomised to surgery and
10 out of 33 participants randomised to observation had died. None of the deaths was caused by
gallstone disease.
A total of 16 out of 102 (16%) participants randomised to observation and 21 out of 99 (21%)
participants randomised to surgery died (Figure 19). The difference between the groups was not
statistically signiﬁcant (risk ratio = 0.73; 95% CI 0.41 to 1.31; p = 0.30).27
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30Relevant outcomes according to the treatment received
by participantsIn both trials, a certain number of participants did not receive the treatment to which they were
randomised but swapped over to receive the other intervention: a proportion of participants randomised
to observation (46 people) underwent cholecystectomy and a proportion of participants randomised to
receive surgery (12 people) opted for conservative management. The ﬂow chart in Figure 20 illustrates the
main outcomes according to the treatment that participants, in both trials, received. Figures 21 and 22
present this information for each trial (Schmidt et al.113 and Schmidt et al.46) separately. Note that in
Figures 20 and 21 the numbers quoted for admission to hospital for gallstone-related pain for the
observation group differ from those in Table 5 as a result of a discrepancy in table III of the Vetrhus
et al. paper.77 Moreover, the discrepancy between the 5 and 14 years’ ﬁndings is because outcomes at
5 years included events which occurred after randomisation but before surgery, whereas outcomes
at 14 years did not include events that took place before surgery.Randomised to surgery
( n = 99)
Randomised to observation
( n = 102)
Operated
( n = 87)
Acute cholecystitis
( n = 1)
Admission for GS-related
pain ( n = 5)
CBD/AP
( n = 1/2)
Acute cholecystitis
( n = 0)
Pain attacks
( n = 12)
CBD/AP
( n = 1/1)
Observed
( n = 12)
Operated
( n = 46)
Observed
( n = 56)
Acute cholecystitis
( n = 0)
Admission for GS-related
pain ( n = 0)
CBD/AP
( n = 0/0)
Acute cholecystitis
( n = 4)
Admission for GS-related
pain ( n = 12)
CBD/AP
( n = 4/0)
Acute cholecystitis
( n = 6)
Admission for GS-related
pain ( n = 7)
CBD/AP
( n = 2/0)
Acute cholecystitis
( n = 0)
Pain attacks
( n = 0)
CBD/AP
( n = 0/0)
Acute cholecystitis
( n = 5)
Pain attacks
( n = 14)
CBD/AP
( n = 3/0)
Acute cholecystitis
( n = 4)
Pain attacks
( n = 12)
CBD/AP
( n = 1/1)
FIGURE 20 Outcomes according to treatment received (both trials combined). AP, acute pancreatitis; GS, gallstone.
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Randomised to surgery
( n = 31)
Randomised to observation
( n = 33)
Operated
( n = 27)
Acute cholecystitis
( n = 1)
Admission for GS-related
pain
( n = 3)
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FIGURE 22 Outcomes according to the treatment received by participants with acute cholecystitis only
(Schmidt et al. 2011).46 AP, acute pancreatitis; GS, gallstone.
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FIGURE 21 Outcomes for the treatment received by participants with uncomplicated symptomatic gallstone disease
only (Schmidt et al. 2011).113 AP, acute pancreatitis; GS, gallstone.
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32Outcomes not included in meta-analysesFurther surgical intervention required
Schmidt et al.113 reported that, at the 14-year follow-up, 4 out of 60 (7%) participants with uncomplicated
symptomatic gallstones (biliary pain only) randomised to surgery who did undergo cholecystectomy
subsequently required endoscopic retrograde cholangiopancreatography. Common bile duct stones were
detected in one of these four participants.Median time to surgery (from randomisation)
Schmidt et al.113 reported that the median time to surgery for participants with uncomplicated
symptomatic gallstones (biliary pain only) was 3 months (range 0–68 months) for participants randomised
to surgery and 28 months for participants randomised to observation (no range was given for the
observation group). Schmidt et al.46 stated that patients who were randomised to surgery, on average,
underwent an operation 4 months (median) after randomisation (range 1–13 months). No details were
provided for those patients randomised to observation who eventually underwent surgery.Quality of life
We were not able to include QoL measures in the statistical analyses as measures of variability were not
reported and were not available from the trial investigators. Quality-of-life measures were assessed only at
5 years. In the paragraphs below, scores for the observation group are reported ﬁrst, followed by scores
for the surgery group. None of the differences between groups was statistically signiﬁcant.Quality of life: Psychological General Well Being Index
In the Schmidt et al. trial113 both intervention groups reported PGWB scores lower than 105 at
6 months, which is the score normally expected in healthy control subjects (mean score of 99.9 for the
observation group and 103.3 for the surgery group, respectively).113 This indicates a slightly poorer level of
general well-being than in healthy control subjects. In addition, the observation group reported lower scores
than the surgery group. This difference was, however, not statistically signiﬁcant. Notably, at this time point,
7 of the 35 participants in the observation group who crossed over to surgery had actually been operated on.
At 6 months, 46 participants with acute cholecystitis reported higher scores and, therefore, greater
well-being than the average score of 105 expected in healthy control subjects (mean score of 110.2 for
the observation group and 106.2 for the surgery group). In contrast to the Schmidt et al. trial,113
participants in the observation group reported higher (but not signiﬁcantly higher) scores than participants
who underwent surgery.
At 12 months, participants in both trials reported levels of well-being lower than those expected of
healthy control subjects. In the Schmidt et al. trial,113 the mean PGWB scores were 101.8 for the
observation group and 102.3 for the surgery group. Similarly, in the Schmidt et al. trial,46 the mean
PGWB scores were 103.1 for the observation group and 103.2 for the surgery group. It is worth noting,
however, that, at this time point, participants’ scores in both trials were similar.
In both trials, participants managed conservatively reported higher well-being scores at 60 months than
those who underwent surgery. In the Schmidt et al. trial,113 the mean PGWB score was 104.1 for the
observation group compared with 101.6 for the surgery group, whereas in the Schmidt et al. trial46
the mean PGWB score was 112.0 for the observation group and 102.5 for the surgery group. In Schmidt
et al. participants randomised to observation reported levels of general well-being greater than scores
which would be expected in healthy control subjects.115Quality of life: Nottingham Health Profile part II
At all time points, both trials reported NHP scores of < 2, indicating a limited number of speciﬁed domains
(i.e. job, housework, social life, home life, sex life, interests/hobbies, holidays) affected by gallstone disease.
In particular, the mean NPH scores for the observation group and the surgery group were, respectively,NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18550 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 551.6 and 1.1,113 and 1.1 and 1.246 at 6 months; 1.6 and 1.0113 and 0.9 and 1.246 at 12 months; and 1.3
and 1.9113 and 0.7 and 1.446 at 60 months. In both trials, scores did not vary signiﬁcantly over time or
between intervention groups.Quality of life: pain score
Pain scores among participants with uncomplicated symptomatic gallstones (biliary pain only)113 showed a
tendency to decrease between 6 and 60 months, with all scores being at the lower end of the possible
range of 0–16. At 6 months, participants in the observation group had a mean score of 4.1 and
participants in the surgery group a mean score of 2.2. At 12 months, the mean score was 3.7 and 2.3 for
the observation group and the surgery group, respectively, whereas at 60 months the scores were 2.4 and
2.0, respectively. Pain scores were consistently higher for the observation group than for the surgery group
(albeit the difference was not statistically signiﬁcant).
Mean scores among participants with acute cholecystitis46 were also generally at the low end of the range
(2.1 and 2.0 at 6 months, 3.1 and 2.4 at 12 months and 1.3 and 2.6 at 60 months for the observation
group and surgery group, respectively). Scores for the surgery group increased between 6 and 60 months
while scores for the observation group increased from 6–12 months and then decreased between 12 and
60 months. Furthermore, at 60 months, pain score for the surgery group was greater than that of the
observation group (the only time point at which this occurred in either of the two trials).Quality of life: Visual Analogue Pain Score
Schmidt et al.113 reported mean VAPS at the lower end of the possible range (0–100) among participants
with biliary pain only (14.7 and 9.4 at 6 months, 15.7 and 7.0 at 12 months and 11.5 and 5.5 at
60 months for the observation group and surgery group, respectively). In particular, scores in the
observation group were consistently higher (but not signiﬁcantly higher) than those in the surgery group.
Pain scores tended to decrease in the surgery group between 6 and 60 months, whereas in the
observation group scores increased between 6 and 12 months and subsequently decreased to
pre-12-month levels at 60 months.
Mean VAPS in participants with acute cholecystitis allocated to surgery46 increased over time while in
participants managed conservatively it varied over time, with a similar trend to that observed in the
Schmidt et al. trial (8.1 and 5.4 at 6 months, 15.1 and 9.9 at 12 months and 6.2 and 11.3 at 60 months
for the observation group and surgery group, respectively).113SummaryThis assessment was based on the clinical data derived from two RCTs (published in six reports) with
a total of 201 participants. Both trials were judged to be at low risk of bias. Table 6 presents a summary
of the outcomes which were included in the meta-analyses. A summary of the clinical effect size for
outcomes assessed at 5 years and for those assessed at 14 years is presented in Figures 23 and 24,
respectively.
Participants randomised to surgery were signiﬁcantly more likely to undergo surgery and had a greater risk
of experiencing surgery-related complications as well as minor complications. Participants randomised to
observation were at signiﬁcantly greater risk of experiencing gallstone-related complications, in particular
acute cholecystitis. Within participants with initial diagnosis of uncomplicated symptomatic gallstone
(biliary pain only), those randomised to observation were more likely to experience pain attacks and be
admitted to hospital for gallstone-related pain than those randomised to surgery. Mortality risk was greater
(but not signiﬁcantly greater) among participants randomised to surgery.33
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TABLE 6 Summary of meta-analysis results (n = 201 in two trials)
Event Risk ratio (95% CI) Test for overall effect (p-value)
Undergoing surgery (14 years) 0.50 (0.34 to 0.73) 0.0004
Pain attacks (14 years) 1.62 (0.43 to 6.17) 0.48
Mortality (14 years) 0.73 (0.41 to 1.31) 0.30
Gallstone-related complications (all 14 years)
Total 6.69 (1.57 to 28.51) 0.01
Acute cholecystitis 9.55 (1.25 to 73.27) 0.03
CBD stones 2.86 (0.47 to 17.59) 0.26
Acute pancreatitis 0.99 (0.06 to 15.44) 0.99
Surgery-related complications (all 5 years)
Total 0.43 (0.21 to 0.91) 0.03
Intra-abdominal infection/bile leakage 1.30 (0.30 to 5.63) 0.73
Wound infection/dehiscence 0.99 (0.06 to 15.44) 0.99
Bile duct injury 0.31 (0.01 to 7.42) 0.47
Reoperation 0.99 (0.06 to 15.44) 0.99
Minor complications 0.11 (0.02 to 0.56) 0.008
Admission due to gallstone-related pain (5 years) 2.69 (0.57 to 12.68) 0.21
Note
A risk ratio of < 1 favours observation.
CLINICAL EFFECTIVENESS OF CHOLECYSTECTOMY COMPARED WITH OBSERVATION/CONSERVATIVE MANAGEMENT
34NIHR Journals Library www.journalslibrary.nihr.ac.uk
Number of participants undergoing surgery
Pain attacks
Gallstone-related complications
  - Acute cholecystitis
  - CBD stones
  - Acute pancreatitis
Surger-related complications
  - Intra-abdominal infection/bile leakage
  - Wound infection/dehiscence
  - Bile duct injury
  - Reoperation
  - Minor complications
Admission due to gallstone-related pain
Mortality rate
0.50 (0.34 to 0.73)
1.62 (0.43 to 6.17)
6.69 (1.57 to 28.51)
9.55 (1.25 to 73.27)
2.86 (0.47 to 17.59)
0.99 (0.06 to 15.44)
Not reported
Not reported
Not reported
Not reported
Not reported
Not reported
Not reported
0.73 (0.41 to 1.31)
0.01 0.10 1 10 100
Favours observation Favours surgery
Risk ratio (95% CI)
FIGURE 24 Summary of meta-analyses results (14-year data) [risk ratio (95% CI)].
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FIGURE 23 Summary of meta-analyses results (5-year data) [risk ratio (95% CI)].
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DOI: 10.3310/hta18550 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 55Chapter 5 Assessment of cost-effectivenessSystematic review of existing cost-effectiveness evidenceA formal systematic review of economic evaluations studies was not attempted as initial scoping literature
searches indicated that there were no existing economic evaluations comparing conservative management
with surgery from the perspective of the UK NHS. Only two cost–utility papers based on the UK setting
were identiﬁed, but they compared early with delayed laparoscopic cholecystectomy.116,119 Therefore, this
chapter focuses on presenting the methods and the results of a de novo economic model.Economic modelling
Model development
A de novo economic model was developed to compare alternative treatment strategies for people with
symptomatic gallstone disease (biliary pain or cholecystitis). According to the purpose of this assessment
two strategies were considered:
l conservative management
l surgical management (cholecystectomy).
The structure of the model was informed by the ﬁndings of the trials included in the systematic review of
clinical effectiveness, other existing evidence, as well as by the advice from health-care professionals within
the research team for this assessment. The perspective adopted for the analysis is that of the UK NHS and
the Personal Social Services.The assumed care pathway of the model
The model described in this chapter is based on two clinically relevant care pathways for gallstone disease:
a surgery care pathway and a conservative management care pathway (Figures 25 and 26). Both pathways
were derived from the care pathway reported in Chapter 2 (Definition of the decision problem). As the
current standard treatment for gallstone disease in the UK is cholecystectomy, the conservative
management pathway portrays a plausible pathway that people with gallstones can follow.
The ﬁrst care pathway (Figure 25) considers patients who are treated with surgery (mainly laparoscopic
cholecystectomy). There are ﬁve health states that could arise from the surgical management: peri- and
post-operative complications, no symptoms, post-surgical symptoms (such as pain that persists after
surgery) and death. Patients who survive surgery can either have no complications or suffer from peri- or
post-operative complications. These complications can either be managed without any further surgical
intervention or require further surgery (e.g. surgery for bile duct injury). Those patients who experience no
complications could end up with symptoms or they could have no symptoms. In subsequent cycles there is
always a chance that patients die when they are in either a symptom or no symptom state from all-cause
age-related mortality.
The second pathway (Figure 26) considers three health states for patients with gallstone disease who are
managed conservatively: no symptoms, symptoms or death. Patients who are free from symptoms after
conservative treatment have a chance of staying in this state (no symptoms) or they may continue to
experience the recurrence of symptoms over time and, therefore, move into a symptoms state. Patients
who continue to experience symptoms have a chance of continuing to be treated conservatively or they
can be offered surgery. As in the surgery pathway, patients always have a chance of dying from all-cause
age-related mortality. The key outcome of the conservative management (number of patients without37
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FIGURE 25 Surgery care pathway. Rectangles represent treatment options; ovals represent health states; arched arrows
above the ovals represent health states in which people may return; and arrows indicate the possible directions in
which individuals could move at the end of each cycle.
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FIGURE 26 Conservative management care pathway. Rectangles represent treatment options; ovals represent health
states; arched arrows above the ovals represent health states in which people may return; and arrows indicate
the possible directions in which individuals could move at the end of each cycle.
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whether or not patients seek any further medical intervention, in particular surgery.Model structure
A Markov model was developed to model the alternative management strategies (i.e. conservative
management or surgery) that patients with symptomatic gallstone disease may be offered over time and
to provide estimates of costs, clinical effectiveness [measured in quality-adjusted life-years (QALYs)] and
cost-effectiveness (Figure 27). The model estimates the costs and consequences of both interventions
and of any further events – such as the treatment for recurrent symptoms and/or complications. The model
was developed using TreeAge Pro 2012 (TreeAge Software, Inc., Williamstown, MA, USA).Sympto...
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40The model was based on a hypothetical cohort of patients presenting with symptomatic gallstone disease
(biliary pain or cholecystitis). In the model, symptomatic patients receive an initial treatment of either
conservative management or surgery (cholecystectomy) and then move into different health states, either
surviving or dying. The assumption that over a given period of time a patient could die is always built into
the model. Death takes into account that patients suffering from gallstone disease (i) are exposed to a very
small risk of death when they undergo surgery and (ii) have a chance of dying from all other causes at any
point in time (this chance is assumed to be equivalent to that of all-cause age-related mortality).118 Death is
referred to as an absorbing state (an absorbing state in a Markov model is a state that once entered
cannot be exited again). Those patients who survive cholecystectomy end up in one of two health states:
they can either have peri- or post-operative complications or they can have no complications for the
remainder of the cycle. Those patients who have post-operative complications (e.g. bile duct injury, port
incisional hernia) remain in the complications post-surgery state for the remainder of the cycle.
Similarly, those patients who have conservative management end up in one of two health states: their
symptoms can either be resolved or they can persist continuously or intermittently over time. It is assumed
that no further treatment is sought by those whose symptoms resolve. Those individuals who continue to
experience symptoms can either undergo surgery or they can continue to be treated conservatively. In the
model it is assumed that all individuals who continue to experience symptoms will present for surgery
within 5 years, so by the end of 5 years all the people left under conservative management are
symptom free.
The following are the key assumptions of the economic modelling exercise:
l The time horizon of the model is 5 years. This time horizon was chosen as long-term follow-up data46
indicate that the majority of people with symptomatic gallstones undergo cholecystectomy during the
ﬁrst 5 years.
l The cycle length (i.e. the time period by which transitions between health states are modelled) is
1 year.
l In the base case, the typical person with symptomatic gallstone disease entering the model is a female
of 51 years of age. This choice is justiﬁed by the average age at which people currently undergo
surgery to remove their gallbladder and by the fact that women are more likely to suffer from gallstone
disease than men.84
The results of the model are presented in terms of incremental cost per QALY. The costs and
beneﬁts incurred beyond 1 year were discounted at 3.5% per year in accordance with the current
National Institute for Health and Care Excellence (NICE) guidelines.119Data requirements and model inputs
Estimations of model probabilities
The model uses probabilities:
l complications after surgery
l resolution of complications
l resolution of symptoms following surgery (symptomatic people can be cured from their
symptoms – cholecystitis/biliary pain following surgery)
l continuing to experience symptoms following initial conservative management;
l transitioning to surgery following conservative management (assumed to be concentrated in
those who continue to experience symptoms
l surgical and all-cause mortality.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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effectiveness reported in Chapter 6 as well as other UK sources. For probabilistic sensitivity analyses,
appropriate probability distributions were assigned.Complications during and after laparoscopic surgery
According to the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) the current rate
of major bile duct injury in laparoscopic cholecystectomy has stabilised at 0.1–0.6%120–126 and series with
no major bile duct injuries have been reported.127 Although many believe that the rate of major bile duct
injury in open cholecystectomy is lower than laparoscopic cholecystectomy, controversy remains.125
Post-operative complications include bile leak, retained stone, wound infection, pneumonia and bile duct
injury. The estimate used in the model for the probability of having peri-operative complications was 0.1
(10%), inclusive of those patients who had their laparoscopic cholecystectomy converted into open
cholecystectomy. This value was based on advice from clinical experts and is a conservative assumption
(in the sense that it is likely to be a lower rate and, based on SAGES data; therefore, our estimates of
cost-effectiveness of surgery are less favourable than they would have been if SAGES data had been used).
An estimate for the proportion of patients whose complications require further surgery was based on the
information available to patients who undergo cholecystectomy in the NHS in England and expert
opinion.128 These values vary from 0.01 to 0.002 (1/100 to 1/500) and the estimate used in the base
analysis was 0.01 (1/100).Symptoms after surgery
Although cholecystectomy is the preferred treatment for symptomatic gallstones, the relationship between
cholecystectomy and post-cholecystectomy symptoms is still unclear.63 Individuals with gallstones have
various abdominal symptoms that may be caused by gallstones or may be present as a separate condition
but with common physiology.50 The accompanying abdominal symptoms are referred to as functional
gastrointestinal disorders. As both functional disorders and gallstones manifest with the same clinical
symptoms (pain and discomfort) it is difﬁcult to distinguish between the two conditions. Lack of clear
distinction makes it difﬁcult to treat the symptoms if they remain after the operation. Existing literature
suggests that a proportion of people may still suffer from persistent or de novo symptoms after
surgery.63,129–131 Post-cholecystectomy syndrome occurs when abdominal symptoms persist after
cholecystectomy. Reports suggest that about 4–40% of individuals who have their gallbladder removed
may continue to experience symptoms after surgery.57–62,132 The probability of having symptoms after
laparoscopic cholecystectomy was informed by existing evidence and advice from clinical experts. The value
used in the base-case analysis was 0.1 (10%).Symptoms and surgery after conservative management
For people with gallstones treated conservatively, the model utilises the probability of individuals
developing symptoms following initial treatment. The probability of experiencing recurrent symptoms while
treated conservatively is based on the ﬁndings of the two RCTs reported in the systematic review of clinical
effectiveness (Chapter 4). The estimate was derived from the number of patients in conservative
management who switched to surgery or required further medical treatment during the 5-year follow-up
period.46 Forty-ﬁve out of 102 symptomatic people received further treatment, mainly surgery, over a
5-year period after randomisation to conservative management. The 5-year probability of presenting for
surgery was converted into a ﬁxed instantaneous rate and was reconverted into an annual probability
using the following formula:133
R ¼ −½lnð1−pÞ/t ð1Þ
where p is the probability, R is the rate, t is the time period of interest and ln is natural log.
The rate based on above data is therefore:
−½lnð1−0.44Þ/5 ¼ 0.115964 ð2Þ41
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42The 1-year probability of having symptoms is therefore:
1-year probability ¼ 1−expð−0.1159641Þ ¼ 0.109493 ð3Þ
The model was speciﬁed so that the proportion of patients remaining symptom free under conservative
management increased over time (as those continuing to experience symptoms presented for surgery).
As such, it was assumed that all those individuals remaining in conservative management at 5 years were
symptom free.Risk of death attached to surgery
This information was based on estimates of risk modelling for the probability of death after
cholecystectomy using simulations for people that received elective surgery.134 The estimate used in the
base-case model was 0.00073 (Table 7).
All-cause mortality rates in the UK
The probability that people with gallstone disease entering the model may die is based on the annual rates
of all-cause age-speciﬁc mortality for both men and women (Table 8).118TABLE 8 All-cause age-speciﬁc mortality rates
Cycle Men Women
0 0.003874 0.002496
1 0.004228 0.002831
2 0.004626 0.003019
3 0.005019 0.003503
4 0.005705 0.003615
TABLE 7 Summary of probability parameters used in model
Deﬁnition Value Distribution Source/notes
Probability surgical mortality 0.00073 Applied deterministically Harrison 2012134
Probability surgical complications 0.10 Applied deterministically Clinical expert advice
Probability symptom free
post-conservative management
0.56 Beta Systematic review
Probability of getting surgery
post-conservative management
0.44 Beta 5-year probability reported in the
systematic review converted to a 1-year
probability within the model
Probability surgical complication
needs further treatment
0.01 Applied deterministically Literature and clinical advice
Probability of having symptoms
after surgery
0.10 Applied deterministically Clinical expert advice
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Costs are presented in pounds sterling (£) in 2011–12 prices. Details of the sources used are summarised
in Table 9. Data included the direct health service costs associated with each treatment strategy. The
following resource use data were required to estimate costs incurred by the NHS: staff time, consumables,
overheads and all the resources associated with any subsequent patient follow-up and management.
Surgical procedures were mapped to their appropriate health-care resource group (HRG) and costed using
NHS Reference Costs84 or the payment by results national tariff. The unit cost data for other resource
utilisation was extracted from the literature or obtained from other relevant sources [e.g. Personal Social
Service Research Unit].
The cost of the surgery was based on the cost of laparoscopic cholecystectomy with the length of stay of
1 day without complications. Laparoscopic cholecystectomy was chosen as it is the most frequently
performed surgical procedure for people presenting with cholecystitis or biliary pain.84 There are two main
dimensions of outcome after laparoscopic cholecystectomy: surgical complications or no complications.
The cost of peri-operative complications was assumed to be the same for both surgical procedures, open
and laparoscopic. Additional costs were considered for those people whose complications required further
surgical interventions such as the treatment of bile duct injury. These additional costs were based on the
average cost of all services relating to hepatobiliary procedures with and without complications. It was also
assumed that these people had four follow-up visits to the hepatobiliary clinic every year. Costs were also
included for people who experienced pain after cholecystectomy (post-cholecystectomy syndrome). People
who had no surgical complications could either be completely cured or alternatively could have suffered
from persistent symptoms (post-cholecystectomy syndrome). Based on clinical advice the cost of unresolved
symptoms was assumed to involve one general practitioner and one outpatient visit per year.TABLE 9 Summary of unit costs used in the analysis
Resource Value Distribution Source/notes
Cholecystectomy surgery £2343 Gamma Elective inpatient HRG data, GA10Da laparoscopic
cholecystectomy, 19 years and over, with length of
stay 1 day or more, without CCs84
Initial conservative management £179 Gamma Consultant led: ﬁrst attendance non-admitted face
to face84
Follow-up conservative management £191 Gamma Based on one hospital outpatient visit (consultant led:
follow-up attendance non-admitted face to face) and
one GP visit £155 + £3684,135
Operative surgical complications £2877 Gamma Elective inpatient HRG data, GA10Fa open or
laparoscopic cholecystectomy with CCs84
Post-operative corrective surgery £6123 Gamma GA03A&Ba to GA013 A&Ba average of hepatobiliary
procedures categories 1–7 with and without CCs84
Post-cholecystectomy syndrome £191 Gamma Based on one hospital outpatient visit (consultant led:
follow-up attendance non-admitted face to face) and
one GP visit £155 + £3684,135
Surgical complications follow-up £532 Gamma Four follow-up outpatient consultant-led visits:
follow-up attendance non-admitted face to face84
Inpatient stayb £949 Gamma Non-elective inpatient (short stay) HRG data. Average of
all endoscopic or percutaneous, hepatobiliary or
pancreatic procedures, with and without complications84
GP visit £36 Gamma Per surgery consultation lasting 11.7 minutes135
CC, complication; GP, general practitioner.
a GA10D, GA10F, GA03A&B and GA013A&B correspond to the speciﬁc codes allocated to the different
hepatobiliary-related treatments.
b Value of cost of non-elective inpatient stay for all types symptomatic people in the conservative management strategy
used in sensitivity analysis.
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44The resources needed to provide conservative management included the number of visits to different
health care providers, in particular the general practitioner (GP) and hospital outpatient department.
In the base-case analysis it was assumed that all people presenting with biliary pain or cholecystitis had
one hepatobiliary consultant clinic visit after the initial presentation (all people in the total cohort had one
initial presentation at clinic). People whose symptoms were not resolved and continued with conservative
management were assumed to have two additional visits within the ﬁrst year of presentation to secondary
care (one to the GP and a follow-up visit to the hepatobiliary clinic) and two similar visits each year in the
following cycles. The remainder of people whose symptoms were not resolved were assumed to have had
laparoscopic surgery and followed the surgery care pathway. Pain relief medications were not considered
in the base-case analysis as these costs are either incurred by the people themselves (rest of the UK) or are
free (Scotland).Estimation of total cost of strategies
The total costs of the treatment strategies were determined by using recursive cost in the Markov model.
As the model tree expands from the left to the right, the ‘cost’ variable is modiﬁed by adding new cost
variables. In this way the value of ‘cost’ at each terminal node is unique to the path from the root node to
that terminal node. Discounted costs are considered in the model to estimate the cost of each strategy by
using the following formula:
Coststrategy ¼ Σcostcycle/ð1þ discount rateÞcycle ð4ÞQuality-of-life measures
Quality-of-life weights associated with the different outcomes of treatment and follow-up of people with
symptomatic gallstones were identiﬁed in order to extend the economic evaluation into a cost–utility
analysis. A focused search of the Cost-effectiveness Analysis Registry (Appendix 1) was performed to
identify QoL data relevant to a UK setting. The search indicated that there were 15 studies reporting utility
weights. None of these studies compared conservative management with cholecystectomy. There were
six papers that compared outcomes of different interventions such as mini laparotomy, lithotripsy, open
cholecystectomy with laparoscopic cholecystectomy116,117,136–139 and one paper compared the different
methods of valuing health-related QoL techniques, i.e. visual analogue scale and the standard gamble in
measuring people preferences for outcomes of gallstone disease.140
Two of the studies117,139 that were conducted alongside RCTs used the European Quality of Life-5
Dimensions (EQ-5D). Although Nilsson and colleagues139 collected data at ﬁve different time points
(pre-operatively, post-operatively, 1 week, 1 month and 1 year), they did not report preference-based
weights or estimate a QALY. Macafee et al.117 compared early with delayed cholecystectomy and reported
utility scores of 0.85 (standard deviation 0.26) for the early group and 0.93 (standard deviation 0.13)
for the conventional (delayed) group (QALYs estimated using the EQ-5D questionnaire were calculated
30–35 days after laparoscopic surgery). The ﬁnal study138 estimated QALYs for different health states
relating to two treatment options using a time trade-off method. The utility score for laparoscopic
cholecystectomy was found to be similar to those of the Macafee et al.117 study, 0.90 (95% CI 0.87 to
0.93). In the model, utility values were assigned to the types of potential different morbidities that could
be associated with the procedures or health state represented in the model. Table 10 provides a summary
of the estimates used in the model. Estimates of the utility for people who had cholecystectomy were
based on the results of a RCT.117 The utility estimate for people whose symptoms were resolved using
laparoscopic cholecystectomy or conservative management was 0.93. The rest of the estimates were based
on a study that used standard gamble to quantify how much a given type of morbidity would detract from
their QoL.140 The estimation of QALY values took into account the time people stayed in the state. For
example, individuals who had further surgery were in a reduced state of health and were assigned a utility
value of 0.64 for a month and 0.80 for the rest of the year. By applying utility weights to the modelled
states and temporary events within states in the Markov model, QALYs gained over the 5-year follow-up
period were tracked.NIHR Journals Library www.journalslibrary.nihr.ac.uk
TABLE 10 Quality-of-life estimates
Health state Utility value Distribution Notes
Symptom-free post-laparoscopic
cholecystectomy
0.93 Beta Based on value of outcome for people who
had conventional laparoscopic surgery117
Symptom-free post-conservative
management
0.93 Beta Assumed to be the same as people who
received laparoscopic surgery117
Post-cholecystectomy syndrome 0.79 Beta Based on standard gamble value of people
having post-cholecystectomy syndrome as a
chronic outcome140
People with persistent symptoms 0.71 Beta Based on Bass’s values for having biliary pain
once a week each month for a lifetime140
Symptoms not resolved in
conservative management
0.80 Beta Based on value of people experience biliary
pain once a month for a life time140
People undergoing corrective surgery 0.64 Beta Based on standard gamble value for people
needing surgery to repair a post-operative
biliary stricture140
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The base-case analysis was based on the costs and outcomes of a cohort of 51-year-old symptomatic
women (the mean age of people receiving cholecystectomy in England and Wales). The outcome is the
incremental cost per QALY. Data on the outcome are presented in two ways. First, the mean costs,
QALYs and the incremental cost-effectiveness ratio (ICER), where appropriate, are calculated. These are
ratios of the differences in costs and interventions divided by the differences in clinical effectiveness
between the different strategies. These data reﬂect the rate of return in QALYs to the quantity of
resources used (measured in monetary values). The second way in which the cost-effectiveness of the
alternative care pathways is presented is in terms of cost-effectiveness acceptability curves (CEACs). CEACs
which are derived from probabilistic sensitivity analysis are used to illustrate the uncertainty caused by the
statistical variability in the parameters used in the model. CEACs illustrate the likelihood that a strategy is
cost-effective at various threshold values for society’s willingness to pay for an additional QALY. The value
society is willing to pay for a QALY is unclear, but in the UK NICE tends to recommend that an
intervention is cost-effective when the incremental cost per QALY is less than £20,000–30,000.119Probabilistic and deterministic sensitivity analyses
Probabilistic and deterministic sensitivity analyses were applied to the model in order to assess the
robustness of the results to realistic variations in the model parameters. The point estimates applied to
costs, outcomes and probabilities of events in the model are all estimates of true population values. As
such, distributions are assigned to these parameters to characterise the surrounding uncertainty due to
sampling variation. Monte Carlo simulation was used to repeatedly sample from the distributions assigned
to the parameters (Tables 7, 9 and 10) and reanalyse the model a large number of times.
Probabilistic sensitivity analyses of the base case were conducted by assuming a beta distribution for
the probability of successful treatment outcome in the conservative management strategy (the 5-year
probability of presenting for surgery being the complement of this). All cost parameters were assigned a
gamma distribution as this distribution ﬁts the skewed nature found in resource use and cost data. For
health-care resource group inpatient unit cost data, the interquartile range was used to derive the
standard error. For the normal distribution this is deﬁned by the interval ± 0.67 standard errors either side
of the mean.133 An estimate of the cost standard error was derived by generating the difference between
the interquartile ranges and dividing it by 2 then multiplying by 0.6, where 0.67 is the critical value which
excludes 50% of the standard normal distribution. There was no distribution attached to all-cause
mortality rate as the estimate was derived from the general population. The utility parameters were45
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46assigned a beta distribution to take into account the constraints in terms of their construction, which is
inﬁnity at the lower end (worst possible health) and 1.0 at the upper end (perfect health).
Sensitivity analyses varied the assumptions and/or parameter point estimates applied in the base-case
analysis. One-way sensitivity analyses (varying the probabilities, costs and QALY weights one at a time)
were performed.The probability of people needing surgery after conservative management
The probability of the number of people needing surgery was varied by 25% as the results of the
systematic review suggested that between 25% and 75% of people needed surgery after
conservative management.Probability of complications during surgery
Waiting lists are a common tool for managing access to elective surgery.141 In the UK, the average
reported time from referral by general practitioner to treatment for gallbladder problems varies greatly in
different health trusts, from 5 to 18 weeks. There is little evidence on the health impact of delaying
surgery for various conditions. According to cholecystectomy guidelines, conversion from laparoscopic to
open cholecystectomy is halved (8% vs. 16%) when operating in the acute phase of the disease as
opposed to allowing the acute phase to settle and being operated on later. The probability of surgical
complications varies between 5% and 20%.142Cost of conservative management
There are no reliable data on the number of visits that people with symptoms of gallstone disease make to
primary care providers before they are referred to a consultant, although it has been suggested that they
may have multiple visits to their GP during the time they are awaiting treatment. The base-case analysis
assumed that people with symptomatic gallstones had one primary care and one consultant visit. The
number of visits was doubled to estimate the impact on cost-effectiveness. Another sensitivity analysis
explored the inclusion of inpatient costs in the conservative management arm. According to the
commissioner’s guide to cholecystectomy, it is not uncommon for a person to be readmitted as an
emergency with a ﬂare of symptoms three times during a prolonged period waiting for surgery.90 A
Canadian study on the risk of emergency while waiting for elective cholecystectomy reported that 6.7%
of participants had emergency admissions.141 Therefore, we estimated the cost of one, two and three
additional inpatient stays for people who had persistent pain attacks while receiving conservative
management. Further analysis was also performed assuming that all symptomatic people receiving
conservative management had 1–3 non-elective episodes of short inpatient stay.Utilities
As mentioned earlier, the data on utilities were based on published data and assumptions were made
about the utility value of people who had received medical management. Although the RCTs included
in the review of clinical effectiveness collected information on the number of pain attacks (within a
pre-speciﬁed range) over a 5-year follow-up period, no data were provided on the duration of the pain
attacks or on the number of pain attacks in each randomised group. Bass and colleagues140 estimated
people preference values for selected outcomes by described frequency of pain or duration of outcome
and their values ranged from 0.62 for having biliary pain once a day for a lifetime to 0.85 for having biliary
pain once a week for 1 month. The CIs for these values spanned between 0.26 and 1.0 (full health).
Therefore, the utility of people that remained symptomatic in the conservative management arm was
increased and decreased by 0.05 increments to explore the impact of this change on the results. Standard
gamble utility weights for those who had open cholecystectomy with and without complications such as
post-operative wound infections ranged from 0.57 to 0.83 for those with post-operative bile duct stone.
Analysis was also performed to estimate the impact of increasing the utility of people who had continuing
surgical complications from 0.64 to 0.80 (closer to the utility value of those patients who had open
cholecystectomy 0.78).NIHR Journals Library www.journalslibrary.nihr.ac.uk
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The NICE guidelines recommend an annual discount rate of 3.5% for costs and outcomes and was applied
in the base-case analysis.119 A range of between 0% and 6% was considered in the sensitivity analyses.Increasing follow-up to 10 years
Evidence from the long-term follow-up studies46,113 suggests that the number of people seeking further
treatment reduces over time, so the base-case analysis considered the 5-year follow-up. A sensitivity
analysis was performed to explore how the small variation in modelled health outcomes and ongoing
management costs (at 5 years) inﬂuences cost-effectiveness over a longer time horizon (10 years).Value of information analysis
The decisions related to the adoption or rejection of technologies should be based on expected
cost-effectiveness given the current existing information. However, the decisions should not be based
on little, or poor-quality evidence, as long as the decision to conduct further research to support adoption
(or rejection) is made simultaneously.132 Decisions to adopt or reject a technology based on existing
information will be uncertain as there will always be a chance that the wrong decision could be made.
Wrong decisions lead to opportunity costs due to forgone health beneﬁts and resources. The expected
cost of uncertainty is determined jointly by the probability that a decision based on existing information
will be wrong and the consequences of a wrong decision. The estimates of the probability of error and
opportunity costs of error can be used to calculate the expected cost of uncertainty or the expected loss
surrounding the decisions. The expected cost of uncertainty can be interpreted as the expected value of
perfect information (EVPI) and perfect information can be used to eliminate the possibility of making the
wrong decision. We performed a value of information analysis to estimate the distribution of expected
costs and expected QALYS of treatment of biliary pain/cholecystitis dependent on the uncertainty in the
input parameters. The net monetary beneﬁt (NMB) for the two strategies from each Monte Carlo iteration
was computed to represent the possible values of NMB for all the possible realisations of the uncertain
parameters. The maximum NMB among all the strategies was then calculated to determine the total EVPI
per subject. The expected value of a decision undertaken with perfect information was derived by
averaging the maximum net beneﬁt with perfect information and the maximum net beneﬁt with the
current information. We then estimated the expected value for the entire population that could potentially
beneﬁt from more research (population EVPI). To calculate the population EVPI, we assumed the effective
lifetime of the treatment to be 10 years. Beneﬁts to future people were discounted at 3.5%. The annual
patient population that could beneﬁt from the results of a future study was based on the number of
people undergoing a gallbladder excision per annum in England (Hospital Episode Statistics data84),
multiplied by the time period of 10 years.Results
Deterministic and probabilistic results
The cost-effectiveness analysis aggregates the average 5-year costs for the treatments and time spent in
each of the various health states of the model. Table 11 shows the results for the base-case analysis for a
hypothetical cohort of 51-year-old women with symptomatic gallstones. The table reports the performance
of surgery compared with conservative management, which is less costly and less effective. On average,
conservative management care pathway costs less but has lower beneﬁts (QALYs) than the surgery
pathway. Analysis performed using a cohort of 51-year-old men had lower QALYs (4.108 for conservative
management and 4.21 for cholecystectomy) but the ICER was similar to that of the base-case analysis
(ICER £12,178).
Probabilistic results
To account for the uncertainty surrounding ICER (for surgery vs. conservative management) resulting from
the joint uncertainty surrounding all the model input parameters, probabilistic sensitivity analysis using
Monte Carlo simulations was performed. The results of the probabilistic analysis are reported in the form47
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TABLE 11 Base-case analysis
Strategy Costs (£) Incremental cost QALYs Incremental QALYs ICER (£)
CM 1104 4.139
Surgery 2340 1236 4.232 0.094 13,205
Probability cost-effective for different threshold values for society’s willingness to pay for a QALY (£)
Threshold value 10,000 20,000 30,000 40,000 50,000
CM 60% 51% 46% 44% 42%
Surgery 40% 49% 54% 56% 58%
CM, conservative management.
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48of CEACs (Figure 28). The conservative management arm has a higher probability of being considered
cost-effective for thresholds below £20,000 and the surgery arm has a higher probability of being
considered cost-effective as the threshold increases beyond £20,000.
Sensitivity analysesProbability of the number of people needing surgery
As anticipated, the value of the ICER doubles when we reduce the probability of people needing surgery
after conservative management to 25%, as the costs of conservative management are reduced and its
effectiveness increases (although the QALYs are still lower than those of the surgery strategy). This is
equivalent to conservative management being targeted on a lower risk group (i.e. a group who have less
frequent symptoms and better QoL than the average observed within the cohort).
On the other hand, the value of the ICER is reduced when the probability of people needing surgery
after conservative management increases to 75%. The cost difference between the two strategies
reduces but the difference between the QALYs increases, hence, making the surgery strategy more
favourable (Table 12).100
95
90
85
80
75
70
65
60
55
50
45
40
35
30
25
20
15
10
5
0
0 5 10 15 20 25 30 35 40 45 50
Willingness-to-pay (£000)
Pr
o
b
ab
ili
ty
 c
o
st
-e
ff
ec
ti
ve
 (
%
)
CM
Surgery
FIGURE 28 Cost-effectiveness acceptability curve determined by society’s willingness to pay for an additional QALY.
CM, conservative management.
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TABLE 12 Cost-effectiveness of conservative management vs. surgery: effect of varying the probability of people
needing surgery after conservative management
Strategy Costs (£) Incremental cost (£) QALYs Incremental QALYs ICER (£)
Probability of people needing surgery after conservative management reduced to 25%
CM 694 – 4.182 – –
Surgery 2340 1646 4.222 0.049 33,542
Probability cost-effective for different threshold values for society’s willingness to pay for a QALY (£)
Threshold value 10,000 20,000 30,000 40,000 50,000
CM 75% 61% 56% 51% 48%
Surgery 25% 39% 44% 49% 52%
Probability of people needing surgery after conservative management increased to 75%
CM 1757 – 4.095 – –
Surgery 2340 583 4.231 0.136 4291
Probability cost-effective for different threshold values for society’s willingness to pay for a QALY (£)
Threshold value 10,000 20,000 30,000 40,000 50,000
CM 52% 49% 47% 46% 46%
Surgery 48% 51% 53% 54% 54%
CM, conservative management.
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The results of varying the probability of complications between 0.05 and 0.20 produced similar results to
those of the base case. The cost of conservative management was lower than surgery, but QALYs were
also lower (Table 13).
Cost of conservative management
The ICER value reduced as the number of inpatient stays (under conservative management) increased
(Table 14). When all the people that had symptoms in the conservative management strategy had an
inpatient stay there was more than 50% chance of the surgery arm being considered to be cost-effective
for the thresholds above £5000.
Changes in the number of outpatient and GP visits had very little impact on the results.Utilities
The ICER results were sensitive to the utility values applied (Table 15). When we assumed that the utility
decrement for people who remain symptomatic under conservative management was greater than in the
base case, the ICER reduced in favour of surgery (this is as expected, as there is more potential for health
improvement if one’s utility value is lower). However, for values above the base case, the results favour
conservative management as QALY gains with surgery decrease.
The analyses which we performed to estimate the impact of increasing the utility of people who had
continuing surgical complications had a low impact on the overall results. On average, both surgery costs
and beneﬁts were higher, and led to a slightly lower ICER than that of the base-case analysis (£14,761).Annual discount rate for costs and benefits
Varying the discount rate for costs did not change the results substantially (Table 16). However, the ICERs
appeared to vary more when the utility discount rate was changed. As expected, the ICER increased as the
rates increased.49
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TABLE 13 Cost-effectiveness of conservative management vs. surgery: effect of varying the probability of
surgical complications
Strategy Costs (£) Incremental cost (£) QALYs Incremental QALYs ICER (£)
Probability of surgical complications is 0.05
CM 1140 – 4.139 – –
Surgery 2427 1287 4.233 0.094 13,739
Probability cost-effective for different threshold values for society’s willingness to pay for a QALY (£)
Threshold value 10,000 20,000 30,000 40,000 50,000
CM 39% 49% 48% 46% 44%
Surgery 61% 51% 52% 54% 56%
Probability of surgical complications is 0.20
CM 1034 – 4.138 – –
Surgery 2166 1133 4.231 0.093
12135
Probability cost-effective for different threshold values for society’s willingness to pay for a QALY (£)
Threshold value 10,000 20,000 30,000 40,000 50,000
CM 59% 50% 47% 45% 44%
Surgery 41% 50% 53% 55% 56%
CM, conservative management.
TABLE 14 Cost-effectiveness of conservative management vs. surgery assuming individuals have an inpatient stay
Strategy Costs (£) Incremental cost (£) QALYs Incremental QALYs ICER (£)
Assuming that the people with persistent pain had one inpatient stay
CM 1455 – 4.139 – –
Surgery 2340 885 4.232 0.094 9455
Probability cost-effective for different threshold values for society’s willingness to pay for a QALY (£)
Threshold value 10,000 20,000 30,000 40,000 50,000
CM 54% 48% 45% 43% 43%
Surgery 46% 52% 55% 57% 57%
Assuming that the people with persistent pain had two inpatient stays
CM 1807 – 4.139 – –
Surgery 2340 533 4.232 0.094 5700
Probability cost-effective for different threshold values for society’s willingness to pay for a QALY (£)
Threshold value 10,000 20,000 30,000 40,000 50,000
CM 48% 44% 43% 42% 41%
Surgery 52% 56% 57% 58% 59%
Assuming that the people with persistent pain had three inpatient stays
CM 2158 – 4.139 – –
Surgery 2340 182 4.232 0.094 1950
ASSESSMENT OF COST-EFFECTIVENESS
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TABLE 14 Cost-effectiveness of conservative management vs. surgery assuming individuals have an inpatient stay
(continued )
Strategy Costs (£) Incremental cost (£) QALYs Incremental QALYs ICER (£)
Probability cost-effective for different threshold values for society’s willingness to pay for a QALY (£)
Threshold value 10,000 20,000 30,000 40,000 50,000
CM 43% 41% 40% 40% 40%
Surgery 57% 59% 60% 60% 60%
Assuming that all the people with symptoms had one inpatient stay
CM 2223 – 4.139 – –
Surgery 2340 117 4.232 0.094 1253
Probability cost-effective for different threshold values for society’s willingness to pay for a QALY (£)
Threshold value 10,000 20,000 30,000 40,000 50,000
CM 42% 40% 40% 39% 39%
Surgery 58% 60% 60% 61% 61%
CM, conservative management.
TABLE 15 Cost-effectiveness of conservative management vs. surgery assuming different utility values for
individuals who remain symptomatic in conservative management
Strategy Costs (£) Incremental cost (£) QALYs Incremental QALYs ICER (£)
Assuming that the utility of those who remain symptomatic in conservative management is 0.60
CM 1104 – 3.936 – –
Surgery 2340 1236 4.232 0.296 4175
Probability cost-effective for different threshold values for society’s willingness to pay for a QALY (£)
Threshold value 10,000 20,000 30,000 40,000 50,000
CM 14% 8% 7% 7% 7%
Surgery 68% 92% 93% 93% 93%
Assuming that the utility of those who remain symptomatic in conservative management is 0.65
CM 1104 – 3.995 – –
Surgery 2340 1236 4.232 0.237 5212
Probability cost-effective for different threshold values for society’s willingness to pay for a QALY (£)
Threshold value 10,000 20,000 30,000 40,000 50,000
CM 20% 12% 10% 10% 9%
Surgery 80% 88% 90% 90% 91%
Assuming that the utility of those who remain symptomatic in conservative management is 0.70
CM 1104 – 4.054 – –
Surgery 2340 1236 4.232 0.178 6936
Probability cost-effective for different threshold values for society’s willingness to pay for a QALY (£)
Threshold value 10,000 20,000 30,000 40,000 50,000
CM 28% 18% 15% 14% 14%
Surgery 72% 82% 85% 86% 86%
continued
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TABLE 15 Cost-effectiveness of conservative management vs. surgery assuming different utility values for
individuals who remain symptomatic in conservative management (continued )
Strategy Costs (£) Incremental cost (£) QALYs Incremental QALYs ICER (£)
Assuming that the utility of those who remain symptomatic in conservative management is 0.75
CM 1104 – 4.113 – –
Surgery 2340 1236 4.232 0.119 10,365
Probability cost-effective for different threshold values for society’s willingness to pay for a QALY (£)
Threshold value 10,000 20,000 30,000 40,000 50,000
CM 40% 26% 22% 21% 20%
Surgery 60% 74% 78% 79% 80%
Assuming that the utility of those who remain symptomatic in conservative management is 0.85
CM 1104 – 4.231 – –
Surgery 2340 1236 4.232 0.001 906528
Probability cost-effective for different threshold values for society’s willingness to pay for a QALY (£)
Threshold value 10,000 20,000 30,000 40,000 50,000
CM 79% 55% 47% 44% 42%
Surgery 21% 45% 53% 56% 58%
Assuming that the utility of those who remain symptomatic in conservative management is 0.90
CM 1104 – 4.29 – –
Surgery 2340 1236 4.232 –0.058 Dominated
Probability cost-effective for different threshold values for society’s willingness to pay for a QALY (£)
Threshold value 10,000 20,000 30,000 40,000 50,000
CM 96% 82% 71% 65% 62%
Surgery 4% 18% 29% 35% 38%
Increasing utility of those that had complications to 0.93
CM 1104 – 4.138 – –
Surgery 2340 1236 4.223 0.085 14549
Probability cost-effective for different threshold values for society’s willingness to pay for a QALY (£)
Threshold value 10,000 20,000 30,000 40,000 50,000
CM 61% 53% 49% 47% 46%
Surgery 39% 47% 51% 53% 54%
CM, conservative management.
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TABLE 16 Cost-effectiveness of conservative management vs. surgery: effect of varying annual discount rates
Discount rate Strategy Cost (£) Incremental cost (£) QALYs Incremental QALYs ICER (£)
Sensitivity analysis varying the cost discount rate
0% CM 1185 – 4.139 – –
Surgery 2350 1165 4.232 0.094 12,454
1% CM 1161 – 4.139 – –
Surgery 2347 1186 4.232 0.094 12,678
2% CM 1138 – 4.139 – –
Surgery 2344 1207 4.232 0.094 12,894
3% CM 1115 – 4.139 – –
Surgery 2342 1226 4.232 0.094 13,103
4% CM 1094 – 4.139 – –
Surgery 2339 1245 4.232 0.094 13,306
5% CM 1073 – 4.139 – –
Surgery 2336 1264 4.232 0.094 13,502
6% CM 1052 – 4.139 – –
Surgery 2334 1281 4.232 0.094 13,691
Sensitivity analysis varying the benefit (QALYs) discount rate
0% CM 1104 – 4.371 – –
Surgery 2340 1236 4.522 0.15 8220
1% CM 1104 – 4.301 – –
Surgery 2340 1236 4.435 0.134 9230
2% CM 1104 – 4.234 – –
Surgery 2340 1236 4.352 0.118 10,505
3% CM 1104 – 4.17 – –
Surgery 2340 1236 4.271 0.102 12,168
4% CM 1104 – 4.109 – –
Surgery 2340 1236 4.194 0.086 14,430
5% CM 1104 – 4.05 – –
Surgery 2340 1236 4.12 0.07 17,689
6% CM 1104 – 3.994 – –
Surgery 2340 1236 4.049 0.054 22,797
CM, conservative management.
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ASSESSMENT OF COST-EFFECTIVENESS
54Increasing follow-up to 10 years
The results moved in the same directions as those of the base-case analysis as the probability of getting
surgery in the conservative management strategy only increased by 0.01. The evidence from the systematic
review of clinical effectiveness indicated that there was only one additional person that received surgery
from the conservative management arm in the 14-year follow-up period bringing the total to 46 out of
102 (45%). There was quite a substantial drop in QALY gain over the longer follow-up period (Table 17).
This was probably because, after 5 years, people on conservative management were no
longer symptomatic.
Value of information
The probabilistic analysis indicated that, for a threshold of £30,000, surgery had a 57% chance of being
considered cost-effective. The expected saving from perfect information per person was £585.91 and the
expected gain in effectiveness was 0.054 per person. The per person EVPI was £2209.65 and the resulting
population EVPI was £1,206,730,653.TABLE 17 Cost-effectiveness of conservative management vs. surgery: effect of increasing the follow-up to 10 years
Strategy Costs (£) Incremental cost (£) QALYs Incremental QALYs ICER (£)
CM 1275 – 7.645 – –
Surgery 2436 1161 7.707 0.062 18,628
Probability cost-effective for different threshold values for society’s willingness to pay for a QALY (£)
Threshold value 10,000 20,000 30,000 40,000 50,000
CM 62% 54% 51% 49% 48%
Surgery 38% 46% 49% 51% 52%
CM, conservative management.
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This assessment sought to answer the following research question posed by the UK National Institute forHealth Research Health Technology Assessment programme: What is the clinical effectiveness and
cost-effectiveness of cholecystectomy for preventing recurrent symptoms and complications from
symptomatic gallstones or cholecystitis?Summary of ﬁndingsThis assessment, using the best available evidence and a health economic model, found that conservative
management is on average less costly than surgery but also less effective for treating symptomatic gallstones.
The results of the economic evaluation were most sensitive to the utility values used for people who were
managed conservatively. The conservative management strategy dominated surgery (i.e. the conservative
management was cheaper and more effective) when the utility value for persistent symptoms was assumed to
be 0.90. However, when the utility value equalled 0.60, surgery was more effective, although more expensive,
giving an ICER of £4175. With changes in the utility value of persistent symptoms from 0.60 to 0.90, the
probability of the surgery strategy being considered cost-effective at a willingness-to-pay threshold of £20,000
changed from 92% to 18%. However, caution should be exercised owing to the uncertainty around some of
the parameters used in the model. The ﬁndings of the clinical effectiveness review indicate that symptomatic
people randomised to observation were at signiﬁcantly greater risk of experiencing gallstone-related
complications (in particular, acute cholecystitis), pain attacks and admissions to hospital for gallstone-related
pain. Symptomatic people randomised to surgery were signiﬁcantly more likely to undergo surgery and had a
greater risk of experiencing surgery-related complications as well as minor complications. Forty-ﬁve per cent of
people originally randomised to observation switched to surgery, whereas 12% of people originally randomised
to surgery avoided the operation. It is interesting that nearly half of people randomised to observation were not
operated on during the long-term follow-up period, demonstrating that there are a proportion of people who
do not require surgery. When we considered outcomes according to the treatment people actually received,
we noticed that people who did not undergo surgery had fewer episodes of pain attacks and fewer admissions
to hospital as a result of pain than people who were treated with cholecystectomy.
Approximately 70,000 cholecystectomies are performed every year in the UK, the majority laparoscopically.
However, surgery could be avoided in a proportion of people with symptoms but no complications, and
this option appears to be safe in terms of subsequent events. The implications of this assessment in terms
of planning the best care pathway for people suffering from gallstone disease are therefore crucial.
Nevertheless, the uncertainty surrounding our ﬁndings and the paucity of the current evidence suggest a
cautious interpretation.Clinical effectiveness
The two included studies46,113 we identiﬁed in the current literature were good-quality RCTs, which
randomised a total of 201 participants with symptomatic gallstone disease to either cholecystectomy or
observation. Both trials reported relevant outcomes, which were combined in mathematical syntheses
when appropriate. It is noteworthy that both trials were conducted in Norway and not in the UK. We do
not know how well the health-care system in Norway mirrors the UK NHS.Gallstone disease associated events
On the whole, signiﬁcantly more people randomised to observation (14%) than to surgery (2%)
experienced gallstone-related complications. New events that occurred in the observation group were
acute cholecystitis, common bile duct stones and acute pancreatitis. In particular, further complications
occurred more frequently (27%) in people with an initial diagnosis of acute cholecystitis46 than in those
(1%) with uncomplicated symptomatic gallstones (biliary pain only).113 Few people suffered from CBD
stones during the 14-year follow-up with no signiﬁcant difference between intervention groups55
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56(4% in the observation group vs. 1% in the surgery group). In particular, CBD stones occurred in only
one person with uncomplicated symptomatic gallstones (biliary pain only) rather than acute cholecystitis
during the 14-year follow-up period. Similarly, the proportion of people suffering from acute pancreatitis
was the same in both intervention groups (1% observation group vs. 1% in the surgery group). These
ﬁndings are in line with those of early natural history studies which report a cumulative rate of 2–6% for
CBD stones or acute pancreatitis in participants observed for 5–10 years.17,42,92 The overall risk of
developing acute biliary complications in people with symptomatic gallstones has been estimated to be
around 3% per annum during an observation period of 6 years.143 In a recent population-based study,12
gallstone-related complications were observed in 7.5% and 22% of mild and severe symptomatic people,
respectively. In short, in the included RCTs, the majority of people treated conservatively did not experience
long-term complications (86%); CBD stones and episodes of acute pancreatitis were both rare.Pain attacks
Overall, the proportion of people suffering from pain attacks was not signiﬁcantly different between
randomised groups (25% in the observation group vs. 12% in the surgery group). Pain attacks were
observed more frequently in participants treated conservatively (26/102 people) than in those who
underwent surgery (12/99 people) and in participants with uncomplicated symptomatic gallstones
(biliary pain only – 23/69 people) rather than in those with an initial diagnosis of acute cholecystitis (3/33).
The admissions to hospital as a result of pain were not signiﬁcantly different between intervention groups.
However, admissions were more frequently observed in people with uncomplicated symptomatic
gallstones (biliary pain only – 12/69) rather than in those with acute cholecystitis (4/33). It is noteworthy
that, when we considered people with gallstones according to the treatment they actually received and
not according to randomisation, fewer episodes of pain were observed in people treated conservatively
(12/68) than in those who were eventually operated on (26/133).
The review ﬁndings on pain attacks are broadly similar to those suggested in the clinical literature,
i.e. cholecystectomy is not always successful in relieving symptomatic people from pain. Up to 40% of
people may suffer from post-cholecystectomy symptoms.56 Symptoms may persist or arise de novo after
surgery.63 Marked biliary pain has been described in 4–9% of people after cholecystectomy, while
persistent abdominal pain or non-speciﬁc pain has been reported in about 13–37% of people.57–62
Some investigators have also reported a persistent pain similar to that experienced pre-operatively in
approximately 20% of people after cholecystectomy.64,65Surgery rate
The majority of people randomised to receive surgery (88%) and approximately half of the people
randomised to observation (45%) eventually underwent cholecystectomy during the 14-year follow-up
period. As few gallstone-related complications were experienced by symptomatic people randomised to
observation, it is likely that pain was the reason why they underwent surgery.114 Most of the surgical
procedures were performed during the ﬁrst 5 years and virtually no operations occurred after 5 years.
These data are in accordance with previously published studies. McSherry and colleagues17 found that
44% of people with mild gallstone disease underwent surgery during a 5-year follow-up period. Similarly,
Festi and colleagues12 reported that 17% and 41% of people with mild and severe symptoms, respectively,
underwent surgery during a 10-year follow-up period, but the majority of the surgical procedures (68%)
were performed during the ﬁrst 4 years.
Not all participants in the observation group required cholecystectomy or experienced severe complications
during the long-term follow-up. Interestingly, 55% of people randomised to observation did not require an
operation during the 14-year follow-up period and 12% of people randomised to receive cholecystectomy
did not undergo the scheduled operation, probably as a result of minimal, tolerable symptoms. These
ﬁndings are in agreement with those of early natural history studies17,45 and with those of more recent
observational and population-based studies.12,56 Larsen and colleagues56 found that 45% of symptomatic
people on watchful waiting were totally relieved of symptoms during a 1-year observation period. Similarly,NIHR Journals Library www.journalslibrary.nihr.ac.uk
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more severe symptoms did not experience further episodes of pain during a follow-up period of 10 years.Surgery associated events
The risk of surgery-related complications including abdominal infection, bile leakage, wound infection,
dehiscence and bile duct injury was signiﬁcantly higher in the cholecystectomy group. Nineteen per cent of
participants originally randomised to surgery, compared with 7% participants randomised to observation
(who were eventually operated on), experienced surgery-related complications. Complications of
cholecystectomy have been well documented and the ﬁndings of our two RCTs46,113 are consistent with
those of three recent Cochrane systematic reviews106,144,145 which indicate that the total number of people
suffering complications after open, small-incision or laparoscopic cholecystectomy is high with no
signiﬁcant differences between the three surgical procedures.106 In particular, the proportions of total
complications after laparoscopic and small-incision cholecystectomy calculated from 13 clinical trials at low
risk of bias (total 2337 participants) were 17% and 17.5%, respectively.106Mortality rate
There were no deaths caused by gallstone disease in the included trials. The all-cause mortality at 14 years
was greater (but not signiﬁcantly greater) among participants randomised to surgery. Even though a
signiﬁcant difference between intervention groups was not detected, it is noteworthy that the relative risk
was 0.73 (95% CI 0.41 to 1.31) favouring the observation group. This ﬁnding suggests that people
undergoing surgery had an increased probability of death compared with non-operated people. A clear
explanation of this ﬁnding is difﬁcult to determine. However, surgery in itself carries an intrinsic mortality
risk, especially if there are pre-existing comorbidities.Quality of life
We were not able to meta-analyse the scores of QoL scales. The trial investigators reported that, overall
non-signiﬁcant differences were observed between participants who underwent cholecystectomy and
those treated conservatively, and no gallstone or surgery-related deaths occurred in the two randomised
groups. Participants in both treatment groups experienced a decline over time in pain scores, and their QoL
scores improved after randomisation. It is noteworthy that participants with more frequent and marked
pain at randomisation were reported to have a higher probability of subsequent gallstone-related events.
For the group with an initial diagnosis of acute cholecystitis, the trial investigators analysed the results
according to the treatment participants actually received and unexpectedly did not ﬁnd any difference
between observed and operated participants. It is likely, however, that the sample size of the two groups
(64 participants in total) was too small to detect statistically signiﬁcant differences.Early compared with delayed surgery
We identiﬁed only two RCTs in the current literature, which compared observation/conservative
management with cholecystectomy. Several RCTs have been conducted on the effects and safety of
early compared with delayed surgery. Although these studies do not focus speciﬁcally on people with
uncomplicated symptomatic gallstone disease or with a ﬁrst episode of biliary pain presenting to secondary
care, and the delayed period is relatively short (a few weeks), it is worth considering the outcomes of
people allocated to ‘delayed surgery’ in terms of complications and need for emergency surgery in light of
our review results. In particular, two Cochrane systematic reviews have been recently published on the
effects of early laparoscopic cholecystectomy compared with delayed cholecystectomy in people with
either acute cholecystitis or biliary pain.72,146
The Cochrane systematic review on early laparoscopic cholecystectomy (less than 7 days from symptom
onset) compared with delayed cholecystectomy (more than 6 weeks after initial admission) in people
with an initial diagnosis of acute cholecystitis146 included ﬁve trials with a total of 451 participants.
No statistically signiﬁcant differences between the two groups were detected for any of the outcomes
considered, including complication rate (bile duct injury odds ratio 0.6; 95% CI 0.15 to 2.70) and57
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58conversion to open cholecystectomy (odds ratio 0.85; 95% CI 0.53 to 1.34). Length of follow-up was not
reported. However, 18% of the people randomised to the delayed group had non-resolution or recurrence
of symptoms before their planned operation and, therefore, required emergency laparoscopic
cholecystectomy. The proportion of these emergency procedures converted to open cholecystectomy
was 45%.
The same authors conducted a systematic review to evaluate the beneﬁts and harms of early compared
with delayed laparoscopic cholecystectomy in participants with biliary pain due to gallstone disease.72 They
identiﬁed only one trial with a total of 75 participants in the literature.87 Morbidity, and in particular severe
morbidity (e.g. acute pancreatitis, bile duct injury, gallbladder perforation), was signiﬁcantly lower in the
early group (0%, 0/35) than in the delayed group (15%, 6/40). Overall, during the delayed period (mean
4.2 months) 35% of people in the delayed group (14/40) required 18 hospital admissions for symptoms
related to gallstone disease (hospital admissions for people in the early group were not reported).
Hospital stay was signiﬁcantly shorter in the early group than in the delayed group (weighted mean
difference −1.25 days; 95% CI −2.05 to −0.45). The trial was at high risk of bias (unclear allocation
concealment, lack of blinding, no sample size calculation and no intention-to-treat analysis) hence its
results can only be interpreted tentatively.Factors influencing the decision to undertake a cholecystectomy
From a clinical point of view, the review ﬁndings suggest that it would be crucial to identify which
characteristics of gallstone disease could predict the evolution of symptoms. In particular, it would be very
important to be able to single out people with uncomplicated symptomatic gallstones who could be
treated conservatively. Unfortunately, at present no deﬁnitive factors have been identiﬁed. Even the
presence of pain in the upper right abdominal quadrant may not consistently be related to gallbladder
stones147 and, overall, the symptoms caused by gallstone disease are still not completely understood,
rendering it difﬁcult to identify people who could beneﬁt from surgery. Furthermore, people vary
considerably in the way they report their symptoms depending on their individual pain threshold as well as
their preference for having or avoiding surgery. At present, in many cases, surgery is offered independently
from the clinical symptoms of people presenting with gallstone disease and without considering the
potential benign course of the disease partly due to the wide diffusion of laparoscopic cholecystectomy.
According to the World Gastroenterology Organisation Practice Guideline148 on gallstone disease, when a
group of nine surgeons were asked to evaluate 252 people who underwent cholecystectomy, they agreed
that surgery was the appropriate option in only 52% of cases and failed to ﬁnd an agreement on 44% of
cases. There is now an indication that removal of the gallbladder may also potentially lead to a slightly
increased risk of colon cancer in women in the long term.149,150Summary
In our assessment, approximately half of the people in the observation group were eventually operated on.
Almost no surgical operations were performed after the ﬁrst 5 years of follow-up. Participants who
underwent cholecystectomy experienced more surgery-related complications and showed a slight,
non-signiﬁcant, increase in mortality rate (all-cause mortality) than those who were treated conservatively.
Conversely, participants in the observation groups had more episodes of cholecystitis, but the incidence of
other gallstone-related complications (e.g. common bile duct stones, acute pancreatitis) was low.
Approximately half of the people in the observation group did not required surgery at long-term indicating
that there is probably a subgroup of people with symptomatic gallstone disease who could be safely
treated conservatively.Summary of findings from the economic model
The economic model was developed using evidence synthesis from three main sources: a systematic review
and meta-analysis of clinical effectiveness, advice from clinical experts and a prior health state valuation
survey. The economic model compared two treatment strategies: conservative management and surgery.
The model compared cumulative costs and QALYs for a cohort of 51-year-old women for a 5-year time
horizon. This time was chosen as the available data indicated that the results did not markedly change if aNIHR Journals Library www.journalslibrary.nihr.ac.uk
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conservative management strategy but was, on average, more effective, and generated 0.094 additional
QALYs. The incremental cost per QALY was £13,205. The incremental cost-effectiveness result indicated
that the conservative management strategy had a 51% chance of being considered cost-effective at
society’s willingness-to-pay threshold of £20,000. The probability of cost-effectiveness was not sensitive to
changes in willingness to pay, when the threshold increased to £30,000, the conservative management
strategy had a 46% chance of being considered cost-effective.
The result of the analysis using a male cohort aged 51 years was similar to that of the base-case analysis.
On average, surgery cost more but was more clinically effective, even though the effectiveness for both
arms was slightly lower (conservative management 4.108 and cholecystectomy 4.21) leading to an ICER of
£12,718. This slight reduction in QALYs was the result of the higher mortality of the male cohort.
The results were sensitive to the probability of the number of people needing surgery in the conservative
management strategy. The systematic review indicated that there was uncertainty around the estimate
derived in the meta-analysis. On average, the cost of the conservative management strategy reduced to
£694 when the probability was reduced to 25% leading to an ICER of £33,542 per QALY for the surgical
strategy. The probability that the conservative management strategy would be considered cost-effective
was between 56% and 61% (for willingness to pay for QALY values of £20,000–30,000, respectively).
However, the ICER reduced to £4291 when the probability of surgery among those initially managed
conservatively was increased to 75%. The probability that the surgery strategy would be considered
cost-effective at the recommended threshold was between 51% and 53%.
There was no evidence to indicate that the risk of surgical intervention increased over time for patients
that required surgery after conservative management. Therefore, these patients were assumed to follow a
similar pathway to those who went straight into surgery. However, the model considered that patients
who had surgery after conservative management had a lower utility prior to surgery – to take into account
the fact that they remained symptomatic.
Evidence suggests that the number of complications from laparoscopic cholecystectomy has reduced over
the years as the procedure has become widely used. The sensitivity analyses results around the probability
of surgical complications were similar to those of the base-case analysis (£13,739 when probability of
complications = 0.05, and £12,135 when probability of complications = 0.2), suggesting that the model is
robust to the changes in the probability of surgical complications.
The results were more sensitive to changes in the costs of conservative management. As there are no data
to support the average number of visits people may have to the GP and the hospital, various exploratory
analyses were performed to assess the impact of additional inpatient stays for people in the conservative
management strategy. As anticipated, as the number of inpatient stays (each year) for the group with
persistent pain increased, the cost of the conservative management strategy increased, thereby reducing
the cost difference between the two strategies. This led to a reduction of the ICER from £13,205
(no inpatient stay) to £1253 (three non-elective inpatient short stays).
The results were most sensitive to the utility value that was used for people who were managed
conservatively. Based on a previous valuation survey, in the base-case analysis it was assumed that the utility
was 0.71 among those with persistent symptoms and 0.80 for those with no persistent pain. As appropriate
information on the number of pain attacks and their impact on QoL was not available from the trial data,
these values could have been over- or underestimated, and were therefore scrutinised in sensitivity analysis.
The ICERs varied from £4175 (when utility value equalled 0.60 for persistent symptoms), to conservative
management strategy dominating surgery when the utility value for persistent symptoms was assumed to
be 0.9. The probability of conservative management strategy being considered cost-effective for society’s
willingness-to-pay thresholds of £20,000–30,000 ranged from 8% to 82%. With changes in the utility
value of persistent symptoms from 0.60 to 0.90, the probability of the surgery strategy being considered59
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60cost-effective at willingness-to-pay threshold of £20,000 changed from 92% to 18%. The results were not
sensitive to changes in the utility of complications associated with surgery. The results were not markedly
sensitive to changes in the discount rates applied to both the costs and the beneﬁts.Strengths and limitations of the assessmentThe methods used to conduct this assessment were detailed and thorough. In particular, we performed
comprehensive literature searches of the major electronic databases and we contacted experts in the ﬁeld
to identify all existing relevant evidence. We reviewed all potential eligible studies for inclusion and we did
not restrict study selection to English-language publications. We assessed the methodological quality of
included studies using the best recommended risk of bias tool. We developed speciﬁc data extraction
forms on pre-speciﬁed outcome parameters and two reviewers independently extracted data from
included studies. Despite all these efforts there is still the possibility that some relevant evidence remains
buried in non-indexed journals or hidden as a result of non-publication.
We identiﬁed only two RCTs from the same investigators (published in six reports) in the current literature
and no non-randomised comparative studies. Both trials, even though at low risk of bias, were of small
sample size and it likely that they were underpowered to detect some important treatment differences
between the interventions. Moreover, as a consequence of the small number of participants, few events
were available for some of the analyses with wide conﬁdence intervals around the estimates of treatment
effect. It is also worth noting that even though statistical heterogeneity was not identiﬁed in the
performed meta-analyses, the small sample sizes may have contributed to a lack of power to detect
statistical heterogeneity.
The two trials did not include post-cholecystectomy symptoms within their outcome measurements. As
cholecystectomy is supposed to completely cure gallstone symptoms, an important outcome to consider
would have been the number of people who still experience pain post surgery. Similarly, little information
was available on the type of ‘conservative’ management – in terms of regimen of medication and GP
visits – for participants in the observation group. Even though ‘episodes of pain’ were recorded in both
intervention groups in both trials, the severity of these episodes was not reported and uncertainty remains
as to how these episodes were subsequently treated. Both trials reported the number of admissions to
hospital as a result of pain but without providing details of what exactly ‘admission to hospital’ entailed.
We were able to contact one of the trials investigators who explained that in Norway, where the trials
were conducted, participants who were admitted to hospital as a result of pain are commonly offered
further imaging and laboratory tests to conﬁrm the nature of the pain before opting for the best medical
or surgical treatment. This is somewhat different from what happens in the UK where further admissions
to hospital as a result of pain are normally treated by surgery, unless contraindicated.
Another limitation of this assessment is that both trials were conducted outside the UK and it is likely that
their ﬁndings cannot be easily generalised to a UK clinical setting. Conservative management is not a
policy that is (or has been) used in the NHS. As such, there was an inherent difﬁculty in extrapolating the
review ﬁndings to the NHS setting. We addressed this difﬁculty by consulting with various clinical experts
in the ﬁeld. However, until prospective data are collected, the exact structure of a conservative
management strategy in the NHS, in the UK, is unknown.
A major challenge in analysing and presenting the results of the included trials was the number of
participants in the observation group who crossed over to receive surgery and similarly, although less
numerous, the number of participants in the surgery group who refused to undergo the operation. We
analysed the outcomes using an intention-to-treat approach (i.e. according to randomisation), which
allows a proper comparison between treatment groups. However, when the number of participants who
did not adhere to the intervention they were originally allocated to is so high, the overall validity of the
results becomes questionable and their interpretation problematic. For this reason we decided to also useNIHR Journals Library www.journalslibrary.nihr.ac.uk
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actually received, regardless of randomisation (Figures 20–22 in Chapter 4). As this approach has the
advantage of comparing the speciﬁc effects of surgery compared with those of pure observation, it does,
however, violate randomisation and potentially introduce biases.
Modelling and estimation of cost-effectiveness were challenging because of the lack of data on many of
the parameters required in the model. As indicated in Chapter 5, considerable effort was made to identify
relevant data and sensitivity analyses were used to explore the impact of uncertainties. There were very
few data on the conservative management strategy, as it is not practised in the UK and the modelling
parameters were based on the best available data. Therefore, the ﬁndings of this study should be
treated cautiously.
The effectiveness of treatment was measured in QALYs which were derived from different sources: a study
published in the UK and a study from the USA that used standard gamble to estimate utility preferences
for different health states. As there were no data relating to the QoL of people that do not receive surgery,
it was assumed that the utility of people who did not progress to surgery in the conservative management
strategy was similar to those that were cured by surgery. This decision was based on the clinical judgement
that people who do not receive surgery are unlikely to be experiencing persistent symptoms and are likely
to be ‘doing well’ under the conservative management approach.
Another assumption made in the model was that all people in the surgery strategy received surgery.
Although there is evidence to suggest that a minority of people do not take up surgery when it is offered,
this assumption was considered to reﬂect the current practice in the UK, as surgery is the recommended
treatment for people presenting with uncomplicated symptomatic gallstones or cholecystitis.
People’s preferences regarding the utility or disutility associated with the delivery of conservative
management relative to surgical treatment (e.g. treatment time, pre-operative anxiety, post-operative pain)
were not explicitly taken into account. People may have preferences over these attributes. Those who
considered the disutility of surgery to outweigh the symptoms they experience would likely not agree to
the procedure. As such, this model applies only to people who are considering surgery as a potential
treatment option. It may be that additional incorporation of these factors among this group would change
the QALY estimates to some degree. Further research to elicit preferences for the process and outcomes of
treatment may be useful to explore the impact of these preferences.
The economic model focused on costs to the NHS. However, there are no data on the number of pain
relief medications that people may procure to take care of their symptoms. There is a need for a
prospective follow-up of people who do not have surgery to have further insight regarding their
health-seeking behaviour, particularly the number of times they visit their GP and other health-care
providers for the management of uncomplicated symptomatic gallstone disease (biliary pain
or cholecystitis).61
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DOI: 10.3310/hta18550 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 55Chapter 7 ConclusionsImplications for health careCholecystectomy, and in particular laparoscopic cholecystectomy, is still the standard treatment for
symptomatic gallstone disease (biliary pain or cholecystitis). The main clinical indication for performing
cholecystectomy is persistent or excruciating pain. The results of this assessment, although associated with
some uncertainty, suggest that uncomplicated symptomatic gallstones may have a more benign natural
course than previously assumed and it is likely that a proportion of patients may not require surgery in the
long term and this seems to be safe in terms of subsequent events.
Cholecystectomy is more costly to the NHS because of the use of resources associated with surgery and
the costs related to the treatment of post-surgery complications. Our modelling does show, however, that
conservative treatment/observation fails to become a cost-effective option when a high proportion of
people develop complications and require emergency surgery. A policy of surgery for all, as opposed to a
policy of conservative management followed by surgery for people whose symptoms persist, is likely to be
more costly but more effective, even though the difference between the two policies is modest. Owing
to the current dearth of evidence for some of the relevant health states for gallstone disease and,
consequently, the uncertainty around some utility values used in the model, the ﬁndings of our economic
evaluation require a cautious interpretation.
At present, our information suggests that in many centres in the UK, cholecystectomy is the default option
for all people with symptomatic gallstone disease with no attempts to identify people who might beneﬁt
from a conservative approach. Approximately 70,000 surgical procedures are performed every year in the
UK and, in many hospitals, people are put on a waiting list and operated electively. However, conservative
management may be a valid option in people presenting with uncomplicated symptoms (biliary pain or
cholecystitis) depending on their age and sex, as well as on the clinical presentation of the disease and the
evolution of symptoms over time. In addition, as uncomplicated symptoms are usually not urgent, it may
be reasonable to take into consideration a non-surgical option ﬁrst, alongside people’s personal preference
and convenience. The recognition of symptoms related to gallstones remains, however, a main challenge
in the management of the disease.Suggested research prioritiesThe main gap in the current evidence is the dearth of randomised trials comparing cholecystectomy with
observation/conservative management in uncomplicated, symptomatic gallstone disease, especially in the
UK setting. For this assessment we identiﬁed only two RCTs,46,113 conducted in Norway, and we are not
aware of any ongoing studies on this topic.
A large, good-quality, clinical trial needs to be undertaken to compare the effects and safety of
conservative management with cholecystectomy in people presenting with uncomplicated symptomatic
gallstones (biliary pain only) or cholecystitis. Ideally, such a trial would be multicentre, with long-term
follow-up, would include a pre-speciﬁed assessment of people’s symptoms, relevant outcome measures,
such as post-cholecystectomy symptoms and QoL measurements, and a full economic evaluation.63
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CONCLUSIONS
64Areas in which further research would be important are the following:
l research based on well-designed clinical trials to compare the effects and safety of observation/
conservative management with cholecystectomy in people presenting with uncomplicated symptomatic
gallstones (biliary pain) or cholecystitis to secondary care
l research based on large, long-term, prospective cohorts or population studies to evaluate the natural
history of symptomatic gallstone disease (including uncomplicated cases) in terms of frequency,
characteristics of disease presentation; evolution of symptoms over time and clinical outcomes
l research to elicit factors that may predict the evolution of symptoms in people with symptomatic
gallstone disease
l research on people’s personal preferences in terms of treatment options and outcomes
l research to identify resource use for people undergoing cholecystectomy (pre-operative assessment,
surgical admissions, post-operative management) and for those receiving conservative management, in
order to develop more robust cost estimates for the UK.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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4. gallstones/
5. cholelithiasis/
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7. (gall?bladder adj3 (empyema or inﬂam$)).tw.
8. (biliary colic or gall?stone$ or cholecystitis or cholecystolithiasis).tw.
9. ((pain or biliary symptom$) adj5 (cholecystitis or cholecystolithiasis or gall?bladder)).tw.
10. or/1-9
11. exp Cholecystectomy/
12. cholecystectom$.tw.
13. ((excis$ or remov$) adj4 gall?bladder).tw.
14. ((surgery or surgical) adj5 (cholecystitis or cholecystolithiasis or gall?bladder)).tw.
15. or/11-14
16. exp clinical trial/
17. randomized controlled trial.pt.
18. controlled clinical trial.pt.
19. randomi?ed.ab.
20. randomly.ab.
21. trial.ab.
22. placebo.ab.
23. drug therapy.fs.
24. groups.ab.
25. comparative study/ use prmz
26. (prospective$ or retrospective$).tw.
27. (compare$ or compara$).ti,ab.
28. or/16-27
29. 10 and 15 and 28
30. (review or editorial or case report$ or letter).pt.
31. exp animals/ not humans/
32. 29 not (30 or 31)
33. limit 32 to yr="1980 -Current"
34. limit 33 to yr="2000-Current"77
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7835. limit 33 to yr="1980-1999"
36. remove duplicates from 34
37. remove duplicates from 35
38. 36 or 37The Cochrane Library (date of inception to September 2012)
URL: www.thecochranelibrary.comSearch terms1. MeSH descriptor Cholecystitis, Acute, this term only
2. MeSH descriptor Cholecystitis, this term only
3. MeSH descriptor Cholecystolithiasis, this term only
4. MeSH descriptor Gallstones, this term only
5. MeSH descriptor Cholelithiasis, this term only
6. (gall*bladder) near/3 (empyema or inﬂam*)
7. biliary colic or gall*stone* or cholecystitis or cholecystolithiasis
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9. (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8)
10. MeSH descriptor Cholecystectomy explode all trees
11. cholecystectom*
12. (excis* or remov*) near/4 (gall*bladder)
13. (surgery or surgical) near/5 (cholecystitis or cholecystolithiasis or gall*bladder)
14. (#10 OR #11 OR #12 OR #13)
15. (#9 AND #14), from 1980 to 2012Database of Abstract of Reviews of Effects – Health Technology Assessment –
NHS Economic Evaluation Database (date of inception to September 2012)
Centre for Reviews and Dissemination URL: www.crd.york.ac.ukSearch terms1. Medical subject heading (MeSH) DESCRIPTOR Cholecystitis
2. MeSH DESCRIPTOR Cholecystitis, Acute
3. MeSH DESCRIPTOR Cholecystolithiasis EXPLODE 2
4. MeSH DESCRIPTOR Cholelithiasis
5. MeSH DESCRIPTOR Gallstones
6. (gallbladder or gall bladder) adj3 (empyema or inﬂam*)
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9. #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8
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12. (excis* or remov*) adj4 (gallbladder or gall bladder)
13. (surgery or surgical) adj5 (cholecystitis or cholecystolithiasis or gallbladder or gall bladder)
14. #10 OR #11 OR #12 OR #13
15. #9 and #14NIHR Journals Library www.journalslibrary.nihr.ac.uk
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Conference Proceedings Citation Index – Science (1990 to 12 September 2012)
URL: www.isiknowledge.comSearch terms1. TS =(cholecystitis or cholecystolithiasis or gallstones or cholelithiasis or biliary colic)
2. TS=((gall-bladder or gall*bladder or gallbladder) near/3 (empyema or inﬂam*))
3. TS=((gall-bladder or gall*bladder or gallbladder or cholecystitis or cholecystolithiasis) near/3 (pain or
symptom*))
4. #3 OR #2 OR #1
5. TS=cholecystectom*
6. TS=((excis* or remov*) near/4 (gall-bladder or gall*bladder or gallbladder))
7. TS=((surgery or surgical) near/5 (cholecystitis or cholecystolithiasis or gall-bladder or gall*bladder or
gallbladder))
8. #7 OR #6 OR #5
9. #8 AND #4
10. TS=(trial* or random* or comparison or compare or comparative or prospective or retrospective)
11. #10 AND #9
12. #11[excluding] Document Types=( LETTER OR EDITORIAL MATERIAL OR NOTE)
13. Timespan=1980-01-01 - 2012-09-12Bioscience Information Service (1956 to 10 September 2011)
URL: www.isiknowledge.comSearch terms1. TS =(cholecystitis or cholecystolithiasis or gallstones or cholelithiasis or biliary colic)
2. TS=((gall-bladder or gall*bladder or gallbladder) near/3 (empyema or inﬂam*))
3. TS=((gall-bladder or gall*bladder or gallbladder or cholecystitis or cholecystolithiasis) near/3 (pain or
symptom*))
4. #3 OR #2 OR #1
5. TS=cholecystectom*
6. TS=((excis* or remov*) near/4 (gall-bladder or gall*bladder or gallbladder))
7. TS=((surgery or surgical) near/5 (cholecystitis or cholecystolithiasis or gall-bladder or gall*bladder or
gallbladder))
8. #7 OR #6 OR #5
9. #8 AND #4
10. TS=(trial* or random* or comparison or compare or comparative or prospective or retrospective)
11. #10 AND #9
12. #11[excluding] Document Types=( LETTER)
13. Timespan=1980-2012Trials
Clinical Trials (date of inception to September 2012)
URL: http://clinicaltrials.gov/Search terms
cholecystectomy AND (cholecystitis OR gallstones OR cholelithiasis OR biliary colic)
gallbladder removal AND (cholecystitis OR cholelithiasis)79
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80World Health Organization Clinical Trials Registry (date of inception to
September 2012)
URL: http://apps.who.int/trialsearch/Search terms
(cholecystitis or gallstones) AND cholecystectomyCurrent Controlled Trials (date of inception to September 2012)
URL: www.controlled-trials.comNational Institute for Health Research Portfolio (date of inception to
September 2012)
URL: http://public.ukcrn.org.uk/search/Conference proceedings from:
Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland.
Association of Laparoscopic Surgeons of Great Britain and Ireland.
British Society of Gastroenterology.Cost-effectiveness
Databases
MEDLINE (1946 to 1 October 2012)
MEDLINE In-Process (8 October 2012)
EMBASE (1974 to 8 October 2012)
Ovid multiﬁle search URL: http://shibboleth.ovid.com/Search terms1. cholecystitis/
2. cholecystitis, acute/
3. cholecystolithiasis/
4. gallstones/
5. cholelithiasis/
6. (gall?bladder adj3 (empyema or inﬂam$)).tw.
7. (biliary colic or gall?stone$ or cholecystitis or cholecystolithiasis).tw.
8. ((pain or biliary symptom$) adj5 (cholecystitis or cholecystolithiasis or gall?bladder)).tw.
9. or/1-8
10. exp *Cholecystectomy/
11. cholecystectom$.ti.
12. ((excis$ or remov$) adj2 gall?bladder).tw.
13. ((surgery or surgical) adj3 (cholecystitis or cholecystolithiasis or gall?bladder)).tw.
14. or/10-13
15. exp "costs and cost analysis"/
16. economics/
17. exp economics,hospital/
18. exp economics,medical/NIHR Journals Library www.journalslibrary.nihr.ac.uk
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20. exp budgets/
21. exp models, economic/
22. exp decision theory/
23. ec.fs.
24. monte carlo method/
25. markov chains/
26. exp health status indicators/
27. cost$.ti.
28. (cost$ adj2 (effective$ or utilit$ or beneﬁt$ or minimis$)).ab.
29. economic$ model$.tw.
30. (economic$ or pharmacoeconomic$ or pharmaco-economic$).tw.
31. (price$ or pricing).tw.
32. (ﬁnancial or ﬁnance or ﬁnances or ﬁnanced).tw.
33. ((value adj2 money) or monetary).tw.
34. markov$.tw.
35. monte carlo.tw.
36. (decision$ adj2 (tree? or analy$ or model$)).tw.
37. (standard adj1 gamble).tw.
38. trade off.tw.
39. or/15-36
40. 9 and 14 and 39
41. exp animals/ not humans/
42. 40 not 41
43. remove duplicates from 42
44. limit 43 to yr="1980 -Current"Science Citation Index (1970 to 10 October 2012)
Conference Proceedings Citation Index – Science (1990 to 10 October 2012)
URL: www.isiknowledge.comSearch terms1. TS =(cholecystitis or cholecystolithiasis or gallstones or cholelithiasis or biliary colic)
2. TS=((gall-bladder or gall*bladder or gallbladder) near/3 (empyema or inﬂam*))
3. TS=((gall-bladder or gall*bladder or gallbladder or cholecystitis or cholecystolithiasis) near/3 (pain or
symptom*))
4. #3 OR #2 OR #1
5. TS=cholecystectom*
6. TS=((excis* or remov*) near/4 (gall-bladder or gall*bladder or gallbladder))
7. TS=((surgery or surgical) near/5 (cholecystitis or cholecystolithiasis or gall-bladder or gall*bladder or
gallbladder))
8. #7 OR #6 OR #5
9. #8 AND #4
10. TS=(economic* or cost* or price* or pricing* or ﬁnanc* or markov* or monte carlo)
11. TS=(decision near/3 (tree* OR analy* OR model*))
12. #11 OR #10
13. #12 AND #9
14. Reﬁned by: [excluding] Document Types=( LETTER OR EDITORIAL MATERIAL)
15. Timespan=1980-01-01 - 2012-10-1081
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82NHS Economic Evaluation Database (date of inception to October 2012)
Centre for Reviews and Dissemination URL: www.crd.york.ac.ukSearch terms1. MeSH DESCRIPTOR Cholecystitis
2. MeSH DESCRIPTOR Cholecystitis, Acute
3. MeSH DESCRIPTOR Cholecystolithiasis EXPLODE 2
4. MeSH DESCRIPTOR Cholelithiasis
5. MeSH DESCRIPTOR Gallstones
6. (gallbladder or gall bladder) adj3 (empyema or inﬂam*)
7. biliary colic or gallstone* or gall stone* or cholecystitis or cholecystolithiasis
8. (pain or biliary symptom*) adj5 (cholecystitis or cholecystolithiasis or gallbladder or gall bladder)
9. #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8
10. MeSH DESCRIPTOR Cholecystectomy EXPLODE 1
11. cholecystectom*
12. (excis* or remov*) adj4 (gallbladder or gall bladder)
13. (surgery or surgical) adj5 (cholecystitis or cholecystolithiasis or gallbladder or gall bladder)
14. #10 OR #11 OR #12 OR #13
15. #9 and #14
16. * IN NHSEED
17. #9 AND #16
18. #14 AND #16
19. #17 OR #18CEA Registry (date of inception to October 2012)
URL: https://research.tufts-nemc.org/cear4/SearchingtheCEARegistry/SearchtheCEARegistry.aspxIDEAS (RePEc) (date of inception to October 2012)
URL: https://ideas.repec.orgQuality of life
Databases
MEDLINE (1946 to week 50 2012)
MEDLINE In-Process (10 December 2012)
EMBASE (1974 to 10 December 2012)
Ovid multiﬁle search URL: http://shibboleth.ovid.com/Search terms1. Quality of life/
2. (euroqol or euro qol or eq5d or eq 5d).tw.
3. (sf36 or sf 36 or short form 36 or shortform 36).tw.
4. (sf6 or sf 6 or short form 6 or shortform 6).tw.
5. (sf12 or sf 12 or short form 12 or shortform 12).tw.
6. (sf16 or sf 16 or short form 16 or shortform 16).tw.
7. (sf20 or sf 20 or short form 20 or shortform 20).tw.
8. or/1,2-7NIHR Journals Library www.journalslibrary.nihr.ac.uk
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10. *cholecystitis, acute/
11. *cholecystolithiasis/
12. *biliary colic/
13. (gall?bladder adj3 (empyema or inﬂam$)).tw.
14. (biliary colic or gall?stone$ or cholecystitis or cholecystolithiasis).tw.
15. ((pain or biliary symptom$) adj5 (cholecystitis or cholecystolithiasis or gall?bladder)).tw.
16. or/9-15
17. 8 and 16
18. (review or editorial or case report$ or letter or conference abstract).pt.
19. exp animals/ not humans/
20. 17 not (18 or 19)
21. cholecystitis/
22. cholecystitis, acute/
23. cholecystolithiasis/
24. gallstones/
25. cholelithiasis/
26. (gall?bladder adj3 (empyema or inﬂam$)).tw.
27. (biliary colic or gall?stone$ or cholecystitis or cholecystolithiasis).tw.
28. ((pain or biliary symptom$) adj5 (cholecystitis or cholecystolithiasis or gall?bladder)).tw.
29. or/21-28
30. exp *Cholecystectomy/
31. cholecystectom$.ti.
32. ((excis$ or remov$) adj2 gall?bladder).tw.
33. ((surgery or surgical) adj3 (cholecystitis or cholecystolithiasis or gall?bladder)).tw.
34. or/30-33
35. exp "costs and cost analysis"/
36. economics/
37. exp economics,hospital/
38. exp economics,medical/
39. economics,pharmaceutical/
40. exp budgets/
41. exp models, economic/
42. exp decision theory/
43. ec.fs.
44. monte carlo method/
45. markov chains/
46. exp health status indicators/
47. cost$.ti.
48. (cost$ adj2 (effective$ or utilit$ or beneﬁt$ or minimis$)).ab.
49. economic$ model$.tw.
50. (economic$ or pharmacoeconomic$ or pharmaco-economic$).tw.
51. (price$ or pricing).tw.
52. (ﬁnancial or ﬁnance or ﬁnances or ﬁnanced).tw.
53. ((value adj2 money) or monetary).tw.
54. markov$.tw.
55. monte carlo.tw.
56. (decision$ adj2 (tree? or analy$ or model$)).tw.
57. (standard adj1 gamble).tw.
58. trade off.tw.
59. or/35-56
60. 29 and 34 and 59
61. exp animals/ not humans/83
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8462. 60 not 61
63. remove duplicates from 62
64. limit 63 to yr="1980 -Current"
65. 20 not 64
66. limit 65 to yr="1980 -Current"NIHR Journals Library www.journalslibrary.nihr.ac.uk
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First author & year:             
                 
Journal: 
 
 
 
 
Extractor initials: 
 
 
 
Date: 
Study aim: 
 
 
 
Participants (i.e. Adults with first episode of symptomatic gallstones and being 
considered for Cholecystectomy in a secondary care setting): 
 
 
 
Intervention: 
      Surgical removal of gallbladder: 
 Open 
 Laparoscopic 
 
Comparator: 
 Observation and/or 
 Conservative treatment (give details below) 
 
Study design: 
 RCT 
 Non-randomised comparative study 
 
Setting: 
 
Multicentre study? 
 Yes (give number of centres __________ ) 
 No 
 
Study start/end dates:                                      
 
Duration of study: 
 87
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88Country: 
 
Source of funding: 
 
Additional information on study design: 
 
 
 
 
Method of patient recruitment:  
 
 
 
Inclusion criteria: 
 
 
 
 
 
Exclusion criteria: 
 
 
 
 
 
Characteristics of participants 
 Group 1 Group 2 All 
Enrolled, n 
 
   
Randomised, n 
 
   
Received treatment, n 
 
   NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18550 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 55Post-randomisation 
exclusions, n 
 
   
Analysed, n 
 
   
Lost to follow-up, n 
 
   
Sex:  
Male (n, %) 
Female (n, %) 
 
   
Age:  
Mean (SD) 
Median (range) 
 
 
 
   
Ethnicity: 
Caucasian 
Black 
South Asian 
Far East Asian 
Chinese 
 
   
Diagnosis: 
Biliary colic, n 
Cholecystitis, n 
 
   
Previous ‘gallstones 
attacks’ 
 
   
Concomitant disease 
 
   89
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90Type of gallstones 
 
   
BMI 
 
   
Baseline QoL 
 
   
ASA score 
 
   
Additional patient information: 
 
 
 
Characteristics of interventions 
 
Intervention: Surgical removal of gallbladder 
 
Type of surgery: 
 
Type of incision: 
 
Delay between presenting to secondary care & surgery: 
 
Cost of operation: 
 
Any other information: 
 
Comparator: Observation (watchful waiting) and/or conservative treatment 
 
Type: 
 
Duration: 
 
Cost: NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18550 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 55 
No of patients requiring surgery: 
 
Any other information: 
 
Outcomes Group 1 Group 2 All 
Recurrence of 
symptoms 
 
   
Complications 
 
   
Number of visits to 
primary care or 
hospital ED 
 
   
Analgesic 
requirements 
 
   
Intervention needed? 
Surgical 
Endoscopic 
Radiological 
 
   
Further medical 
intervention 
needed? E.g. incidental 
cancer diagnosis 
 
   
Surgery-related 
morbidity 
 
   
Quality of life 
 
   91
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92Cost of initial and any 
subsequent treatment 
 
   
Mortality 
 
   
Other important 
outcomes reported 
 
   
  NIHR Journals Library www.journalslibrary.nihr.ac.uk
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Schmidt et al. 2011113Schmidt M, Søndenaa K, Vetrhus M, Berhane T, Eide GE. A randomized controlled study of uncomplicated
gallstone disease with a 14-year follow up showed that operation was the preferred treatment. Dig Surg
2011;28:270–6.Secondary publications:
Vetrhus M, Soreide O, Solhaug JH, Nesvik I, Søndenaa K. Symptomatic, non-complicated gallbladder stone
disease. Operation or observation? A randomized clinical study. Scand J Gastroenterol 2002;37:834–839.
Vetrhus M, Soreide O, Eide GE, Solhaug JH, Nesvik I, Søndenaa K. Pain and quality of life in patients with
symptomatic, non-complicated gallbladder stones: Results of a randomized controlled trial. Scand J
Gastroeneterol 2004; 39:270–6.Schmidt et al. 201146Schmidt M, Søndenaa K, Vetrhus M, Berhane T, Eide GE. Long-term follow-up of a randomized controlled
trial of observation versus surgery for acute cholecystitis: non-operative management is an option in some
patients. Scand J Gastroenterol 2011;46:1251–6.Secondary publications
Vetrhus M, Soreide O, Nesvik I, Søndenaa K. Acute cholecystitis: delayed surgery or observation.
A randomized clinical trial. Scand J Gastroenterol 2003;38:985–90.
Vetrhus M, Soreide O, Eide GE, Nesvik I, Søndenaa K. Quality of life and pain in patients with acute
cholecystitis. Results of a randomized clinical trial. Scand J Surg 2005;94:34–9.Excluded studies
Ineligible comparator
Ahmad I. Cholecystectomy in acute cholecystitis. J Pak Med Assoc 1992;42:112–15.
Ajao OG, Al-Saigh AA, Malatani T, Ladipo JK. Timing of surgery in acute cholecystitis. East Afr Med J
1991;68:490–5.
Al-Khuwaitir S. Early versus delayed surgery for acute cholecystitis. J Pak Med Assoc 1984;34:210–13.
Banz VM, Gsponert T, Candinas D, Guller U. Population-based analysis of 4126 patients with acute
cholecystitis: deﬁning the optimal time-point for laparoscopic cholecystectomy. Surg Endosc 2011;25:S2.
Cameron IC, Chadwick C, Phillips J, Johnson AG. Acute cholecystitis – room for improvement? Ann R Coll
Surg Engl 2002;84:10–13.
Chang TC, Lin MT, Wu MH, Wang MY, Lee PH. Evaluation of early versus delayed laparoscopic
cholecystectomy in the treatment of acute cholecystitis. Hepato-Gastroenterology 2009;56:26–8.
Eitan A, Toledano C, Rivlin E, Linn S, Barzilai A. Early vs. delayed cholecystectomy for acute cholecystitis.
Harefuah 1991;120:319–68.97
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98Fowkes FG, Gunn AA. The management of acute cholecystitis and its hospital cost. Br J Surg
1980;67:613–17.
Gomez-Ferrer F, Ortega J, Cortes J, Ruiz J, Arnal C. Early or delayed operations in acute cholecystitis.
Rev Esp Enferm Apar Dig 1988;73:259–63.
Isoda N, Ido K, Kawamoto C, Suzuki T, Nagamine N, Ono K, et al. Laparoscopic cholecystectomy in
gallstone patients with acute cholecystitis. J Gastroenterol 1999;34:372–5.
Jaeger G, Rothenbuhler JM, Famos M, Tondelli P. When should cholecystectomy in acute cholecystitis be
planned? Schweiz Med Wochenschr 1983;113:552–4.
Jarvinen HJ, Hastbacka J. Early cholecystectomy for acute cholecystitis: a prospective randomized study.
Ann Surg 1980;191:501–5.
Johansson M, Thune A, Lundell L. A prospective randomised trial comparing early versus delayed
laparoscopic cholecystectomy in the treatment of acute cholecystitis. Gastroenterology 2002;123:24.
Johansson M, Thune A, Blomqvist A, Nelvin L, Lundell L. Management of acute cholecystitis in the
laparoscopic era: results of a prospective, randomized clinical trial. J Gastrointest Surg 2003;7:642–5.
Johansson M, Thune A, Blomqvist A, Nelvin L, Lundell L. Impact of choice of therapeutic strategy for acute
cholecystitis on patient’s health-related quality of life. Results of a randomized, controlled clinical trial.
Dig Surg 2004;21:359–62.
Kontopodis N, Spiridakis K, Panagiotakis G, Grigoraki M, Kokkinakis T, Rokadakis L. Acute cholecystitis:
conservative treatment and delayed cholecystectomy. Chirurgia 2011;24:121–4.
Kozelj M, Flis V, Potrc S, Horvat M, Mursak M. Comparison between delayed and early cholecystectomy in
acute cholecystitis. J Hepatol 1996;25:209.
Lai PB, Kwong KH, Leung KL, Kwok SP, Chan AC, Chung SC, et al. Randomized trial of early versus
delayed laparoscopic cholecystectomy for acute cholecystitis. Br J Surg 1998;85:764–7.
Lawrentschuk N, Hewitt PM, Pritchard MG. Elective laparoscopic cholecystectomy: implications of
prolonged waiting times for surgery. ANZ J Surg 2003;73:890–3.
Lin A, Stiven P, Bagshaw P, Connor S. Cholecystectomy following acute presentation to a major New
Zealand metropolitan hospital: change to the timing of surgery is needed. N Z Med J 2006;119:U2104.
Mare LD, Saadi A, Roulin D, Demartines N, Halkic N. Delayed versus early laparoscopic cholecystectomy for
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Br J Surg 1983;70:163–5.
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